Envoy Medical (COCH) S-1/A 14 Feb 24 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2023
Document Information Line Items
Entity Registrant Name	Envoy Medical, Inc.
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Entity Central Index Key	0001840877
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022		Dec. 31, 2021
Current assets:
Cash	$ 7,440	$ 183		$ 1,121
Restricted cash – dividends	5,400
Restricted cash – other	4,000
Accounts receivable, net	109	41		88
Other receivable	1,000
Inventories	1,397	1,295		1,060
Prepaid expenses and other current assets	997	129		167
Total current assets	20,343	1,648		2,436
Property and equipment, net	378	331		188
Operating lease right-of-use assets (related party)		577
Total assets	21,215	2,556		2,624
Current liabilities:
Accounts payable	3,381	1,003		661
Accrued expenses	4,052	608		475
Payable to related party	4,000
Operating lease liability, current portion (related party)		125
Product warranty liability, current portion	228	335		248
FPA put option liability	34
Forward purchase agreement warrant liability	846
Total current liabilities	12,690	2,519		1,384
Product warranty liability, net of current portion	2,025	2,143		2,750
Operating lease liabilities, net of current portion (related party)		565
Warrant liability	1,274
Total liabilities	16,429	38,751		27,611
Commitments and contingencies (see Note 14)
Stockholders’ deficit:
Additional paid-in capital	255,912	189,904		185,182
Accumulated deficit	(251,012)	(225,985)		(210,062)
Accumulated other comprehensive loss	(116)	(115)		(108)
Total stockholders’ equity (deficit)	4,786	(36,195)		(44,960)
Total liabilities and stockholders’ equity (deficit)	21,215	2,556		2,624
Series A Preferred Stock
Stockholders’ deficit:
Series A Preferred stock, $0.0001 par value; 10,000,000 and zero shares authorized as of September 30, 2023, and December 31, 2022, respectively; 4,500,000 and zero shares issued and outstanding as of September 30, 2023, and December 31, 2022, respectively			[1]		[1]
Class A Common Stock
Stockholders’ deficit:
Class A Common stock, $0.0001 par value; 400,000,000 shares and 232,000,000 shares authorized as of September 30, 2023, and December 31, 2022, respectively; 19,549,982 and 10,122,581 shares issued and outstanding as of September 30, 2023, and December 31, 2022, respectively	2	1	[1]	1	[1]
Previously Reported
Current assets:
Total current assets	22,729
Total assets	23,601
Current liabilities:
FPA put option liability
Forward purchase agreement warrant liability	1,793
Total current liabilities	13,603
Total liabilities	17,342
Stockholders’ deficit:
Additional paid-in capital	257,385
Total stockholders’ equity (deficit)	6,259	(36,195)		(24,987)
Total liabilities and stockholders’ equity (deficit)	23,601
Related Party
Current assets:
Operating lease right-of-use assets (related party)	494	577
Current liabilities:
Convertible notes payable, current portion (related party)		448
Operating lease liability, current portion (related party)	149	125
Convertible notes payable, net of current portion (related party)		33,397		23,477
Operating lease liabilities, net of current portion (related party)	440	565
Warrant liability (related party)		$ 127
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares		Sep. 30, 2023	Dec. 31, 2022		Dec. 31, 2021
Series A Preferred Stock
Preferred stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001	[1]	$ 0.0001	[1]
Preferred stock, shares authorized		10,000,000	0
Preferred stock, shares issued		4,500,000	0	[1]	0	[1]
Preferred stock, shares outstanding		4,500,000	0	[1]	0	[1]
Class A Common Stock
Common stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001	[1]	$ 0.0001	[1]
Common stock, shares authorized		400,000,000	232,000,000
Common stock, shares issued		19,549,982	10,122,581	[1]	10,123,187	[1]
Common stock, shares outstanding		19,549,982	10,122,581	[1]	10,123,187	[1]
Previously Reported | Series A Preferred Stock
Preferred stock, shares authorized	[1]		10,000,000		0
Previously Reported | Class A Common Stock
Common stock, shares authorized	[1]		400,000,000		400,000,000
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022		Dec. 31, 2021
Income Statement [Abstract]
Net revenues	$ 80	$ 57	$ 221	$ 217	$ 237		$ 310
Costs and operating expenses:
Cost of goods sold	189	106	555	347	957		769
Research and development	1,850	935	5,901	3,532	4,516		3,939
General and administrative	1,426	812	5,401	2,138	3,470		2,473
Total costs and operating expenses	3,465	1,853	11,857	6,017	8,943		7,181
Operating loss	(3,385)	(1,796)	(11,636)	(5,800)	(8,706)		(6,871)
Other expense:
Gain (loss) from changes in fair value of convertible notes payable (related party)	4,902	574	(13,332)	1,473	(7,090)		(1,748)
Other income (expense)	46	(117)	(59)	(119)	(127)		(56)
Total other income (expense), net	4,948	457	(13,391)	1,354	(7,217)		(1,804)
Net income (loss)	1,563	(1,339)	(25,027)	(4,446)	(15,923)		(8,675)
Net income (loss) attributable to common stockholders, basic	1,360	(1,339)	(25,027)	(4,446)	$ (15,923)		$ (8,675)
Net income (loss) attributable to common stockholders, diluted	$ 1,404	$ (1,339)	$ (25,027)	$ (4,446)
Net income (loss) per share attributable to common stockholders, basic (in Dollars per share)	$ 0.13	$ (0.13)	$ (2.46)	$ (0.44)	$ (1.57)		$ (0.86)
Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share)	$ 0.13	$ (0.13)	$ (2.46)	$ (0.44)	$ (1.57)		$ (0.86)
Weighted-average common stock outstanding, basic (in Shares)	10,214,183	10,123,187	10,153,564	10,123,187	10,123,169	[1]	10,126,825	[1]
Weighted-average common stock outstanding, diluted (in Shares)	11,215,068	10,123,187	10,153,564	10,123,187	10,123,169		10,126,825
Other comprehensive loss:
Foreign currency translation adjustment	$ (1)	$ (3)	$ (1)	$ (3)	$ (7)		$ (10)
Other comprehensive loss	(1)	(3)	(1)	(3)	(7)		(10)
Comprehensive income (loss)	$ 1,562	$ (1,342)	$ (25,028)	$ (4,449)	$ (15,930)		$ (8,685)
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parentheticals) - $ / shares		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net income (loss) per share attributable to common stockholders, diluted		$ (0.13)	$ (0.08)
Weighted-average common stock outstanding, diluted	[1]	139,162,385	139,219,864
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Consolidated Statements of Shar

Consolidated Statements of Shareholders’ Deficit - USD ($) $ in Thousands	Previously Reported Redeemable Convertible Preferred Stock	Previously Reported Series A Preferred Stock	Previously Reported Common Stock	Previously Reported Additional Paid-in Capital	Previously Reported Accumulated Deficit	Previously Reported Preferred Stock	Previously Reported	Redeemable Convertible Preferred Stock	Series A Preferred Stock	Class A Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Preferred Stock	Total
Balance at Dec. 31, 2020								$ 19,973			$ 1,393	$ 158,551	$ (201,387)	$ (98)	$ (41,541)
Balance (in Shares) at Dec. 31, 2020								4,000,000			139,225,172
Retrospective application of Merger								$ (19,973)			$ (1,392)	21,365			19,973
Retrospective application of Merger (in Shares)								(4,000,000)			(129,098,010)
Adjusted Balances, beginning of period											$ 1	179,916	(201,387)	(98)	(21,568)
Adjusted Balances, beginning of period (in Shares)											10,127,162
Common stock surrendered												1
Common stock surrendered (in Shares)											(3,975)
Related party note and accrued interest surrendered												68			68
Foreign currency translation adjustment														(10)	(10)
Deemed capital contribution from related party												5,198			5,198
Net income (loss)													(8,675)		(8,675)
Balance at Dec. 31, 2021			$ 1	$ 185,182	$ (210,062)	$ (108)	$ (24,987)	$ 19,973		$ 1,392		163,818	(210,062)	(108)	(44,960)
Balance (in Shares) at Dec. 31, 2021			10,123,187					4,000,000		139,162,672
Retrospective application of Merger								$ (19,973)		$ (1,391)		21,364			19,973
Retrospective application of Merger (in Shares)								(4,000,000)		(129,039,485)
Adjusted Balances, beginning of period										$ 1		185,182	(210,062)	(108)	(24,987)
Adjusted Balances, beginning of period (in Shares)										10,123,187
Foreign currency translation adjustment														2	2
Deemed capital contribution from related party												1,268			1,268
Net income (loss)													(1,871)		(1,871)
Balance at Mar. 31, 2022										$ 1		186,450	(211,933)	(106)	(25,588)
Balance (in Shares) at Mar. 31, 2022										10,123,187
Balance at Dec. 31, 2021			$ 1	185,182	(210,062)	(108)	(24,987)	$ 19,973		$ 1,392		163,818	(210,062)	(108)	(44,960)
Balance (in Shares) at Dec. 31, 2021			10,123,187					4,000,000		139,162,672
Net income (loss)															(4,446)
Balance at Sep. 30, 2022										$ 1		189,073	(214,508)	(111)	(25,545)
Balance (in Shares) at Sep. 30, 2022										10,123,187
Balance at Dec. 31, 2021			$ 1	$ 185,182	$ (210,062)	$ (108)	(24,987)	$ 19,973		$ 1,392		163,818	(210,062)	(108)	(44,960)
Balance (in Shares) at Dec. 31, 2021			10,123,187					4,000,000		139,162,672
Common stock surrendered
Common stock surrendered (in Shares)											(606)
Foreign currency translation adjustment														(7)	(7)
Deemed capital contribution from related party												4,722			$ 4,722
Merger, net of redemptions and transaction costs (in Shares)															2,500,000
Net income (loss)													(15,923)		$ (15,923)
Balance at Dec. 31, 2022							(36,195)			$ 1	$ 1	189,904	(225,985)	(115)	(36,195)
Balance (in Shares) at Dec. 31, 2022										10,122,581	10,122,581
Balance at Mar. 31, 2022										$ 1		186,450	(211,933)	(106)	(25,588)
Balance (in Shares) at Mar. 31, 2022										10,123,187
Foreign currency translation adjustment														(2)	(2)
Deemed capital contribution from related party												645			645
Net income (loss)													(1,236)		(1,236)
Balance at Jun. 30, 2022										$ 1		187,095	(213,169)	(108)	(26,181)
Balance (in Shares) at Jun. 30, 2022										10,123,187
Foreign currency translation adjustment														(3)	(3)
Deemed capital contribution from related party												1,978			1,978
Net income (loss)													(1,339)		(1,339)
Balance at Sep. 30, 2022										$ 1		189,073	(214,508)	(111)	(25,545)
Balance (in Shares) at Sep. 30, 2022										10,123,187
Balance at Dec. 31, 2022							(36,195)			$ 1	$ 1	189,904	(225,985)	(115)	(36,195)
Balance (in Shares) at Dec. 31, 2022										10,122,581	10,122,581
Foreign currency translation adjustment														1	1
Deemed capital contribution from related party												1,952			1,952
Net income (loss)													(13,253)		(13,253)
Balance at Mar. 31, 2023										$ 1		191,856	(239,238)	(114)	(47,495)
Balance (in Shares) at Mar. 31, 2023										10,122,581
Balance at Dec. 31, 2022							(36,195)			$ 1	$ 1	189,904	(225,985)	(115)	$ (36,195)
Balance (in Shares) at Dec. 31, 2022										10,122,581	10,122,581
Merger, net of redemptions and transaction costs (in Shares)															2,500,000
Issuance of Series A Preferred Stock to PIPE Investors (in Shares)															425,606
Net income (loss)															$ (25,027)
Balance at Sep. 30, 2023							6,259			$ 2		255,912	(251,012)	(116)	4,786
Balance (in Shares) at Sep. 30, 2023									4,500,000	19,549,982
Balance at Mar. 31, 2023										$ 1		191,856	(239,238)	(114)	(47,495)
Balance (in Shares) at Mar. 31, 2023										10,122,581
Foreign currency translation adjustment														(1)	(1)
Deemed capital contribution from related party												15,714			15,714
Net income (loss)													(13,337)		(13,337)
Balance at Jun. 30, 2023										$ 1		207,570	(252,575)	(115)	(45,119)
Balance (in Shares) at Jun. 30, 2023										10,122,581
Foreign currency translation adjustment														(1)	(1)
Deemed capital contribution from related party												1,036			1,036
Exchange of redeemable convertible preferred share for Class A Common stock in connection with Merger
Conversion of Convertible Notes into Class A Common stock in connection with Merger										$ 1		27,493			27,494
Conversion of Convertible Notes into Class A Common stock in connection with Merger (in Shares)										4,874,707
Conversion of Envoy Bridge Note into Series A Preferred stock in connection with Merger												10,982			10,982
Conversion of Envoy Bridge Note into Series A Preferred stock in connection with Merger (in Shares)									1,000,000
Preferred stock subscriptions												2,000			2,000
Net exercise of warrants (related party)
Net exercise of warrants (related party) (in Shares)										2,702
Merger, net of redemptions and transaction costs												(1,785)			(1,785)
Merger, net of redemptions and transaction costs (in Shares)									2,500,000	4,115,874
Meteora forward purchase agreement shares as restated												(1,384)			(1,384)
Meteora forward purchase agreement shares as restated (in Shares)										434,118
Issuance of Series A Preferred Stock to PIPE Investors												10,000			10,000
Issuance of Series A Preferred Stock to PIPE Investors (in Shares)									1,000,000
Net income (loss)													1,563		1,563
Balance at Sep. 30, 2023							$ 6,259			$ 2		$ 255,912	$ (251,012)	$ (116)	$ 4,786
Balance (in Shares) at Sep. 30, 2023									4,500,000	19,549,982

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (25,027)	$ (4,446)	$ (15,923)	$ (8,675)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	85	49	75	71
Loss on sale of property and equipment				1
Change in fair value of convertible notes payable (related party)	13,332	(1,473)	7,090	1,748
Change in fair value of warrant liability (related party)	104	23	35
Gain on exercise and cancellation warrant liability (related party)	(231)
Change in operating lease right-of-use assets (related party)	83	82	119
Increase in inventory reserve	(122)	(11)	(41)	1
Changes in operating assets and liabilities:
Accounts receivable	(68)	(9)	47	(19)
Inventories	20	(226)	(194)	55
Prepaid expenses and other current assets	(868)	(37)	38	(23)
Accounts payable	2,378	(241)	342	227
Operating lease liabilities (related party)	(101)	28	(6)
Accrued expenses	694	(104)	133	(153)
Product warranty liability	(225)	(61)	(520)	(169)
Payable to related party	4,000
Net cash used in operating activities	(5,946)	(6,426)	(8,805)	(6,936)
Cash flows from investing activities
Purchases of property and equipment	(132)	(177)	(218)	(125)
Net cash used in investing activities	(132)	(177)	(218)	(125)
Cash flows from financing activities
Proceeds from the issuance of convertible notes payable (related party)	10,000	6,000	8,000	8,000
Proceeds from the PIPE Transaction, the Forward Purchase Agreement, and the Business Combination, net of transaction costs	11,736
Proceeds from the additional Series A Preferred Shares subscription	1,000
Issuance of warrants (related party)		92	92	58
Net cash provided by financing activities	22,736	6,092	8,092	8,058
Effect of exchange rate on cash, cash equivalents, and restricted cash	(1)	(1)	(7)	(10)
Net increase (decrease) in cash, cash equivalents, and restricted cash	16,657	(512)	(938)	987
Cash and restricted cash at beginning of period	183	1,121	1,121	134
Cash and restricted cash at end of period	16,840	609	183	1,121
Supplemental disclosures of cash flow information
Cash paid for interest
Cash paid for income taxes
Noncash investing and financing activity
SPAC excise tax liability recognized upon the Business Combination	2,248			68
Deemed capital contribution from related party upon issuance of 2012 Convertible Notes	$ 18,702	$ 3,891	$ 4,722	$ 5,198

Nature of the Business and Basi

Nature of the Business and Basis of Presentation (restated)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Nature of the Business and Basis of Presentation [Abstarct]
Nature of the Business and Basis of Presentation	1. Envoy Medical, Inc. (“Envoy Medical” or the “Company”) is a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Envoy Medical’s technologies are designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they desire. The Company’s first commercial product, the Esteem, is a fully implanted active middle ear hearing device. The Esteem was approved for sale in 2010 by the United States Food and Drug Administration (“FDA”). Envoy Medical believes the fully implanted Acclaim ® -of-its-kind On September 29, 2023 (the “Closing Date”), a merger transaction between Envoy Medical Corporation (“Envoy”), Anzu Special Acquisition Corp I (“Anzu”) and Envoy Merger Sub, Inc., a directly, wholly owned subsidiary of Anzu (“Merger Sub”) was completed (the “Merger” or “Business Combination”, see Note 3) pursuant to the business combination agreement, dated as of April 17, 2023 (as amended, the “Business Combination Agreement”) . In connection with the closing of the Merger (the “Closing”), Merger Sub merged with Envoy, with Envoy surviving the merger as a wholly owned subsidiary of Anzu. In connection with the Closing, Anzu changed its name to Envoy Medical, Inc. The Company’s Class A common stock, par value $0.0001 per share (“New Envoy Class A Common Stock”), and the Company’s warrants commenced trading on the Nasdaq Stock Market LLC (“Nasdaq”) on October 2, 2023 under the symbols “COCH” and “COCHW,” respectively. On April 17, 2023, prior to entering into the Business Combination Agreement, Anzu and Envoy entered into an agreement (as amended to date, the “Forward Purchase Agreement” or “FPA”) with Meteora Special Opportunity Fund I, LP (“MSOF”), Meteora Capital Partners, LP (“MCP”), Meteora Select Trading Opportunities Master, LP (“MSTO”) and Meteora Strategic Capital, LLC (“MSC” and, collectively with MSOF, MCP and MSTO, the “Sellers” or “Meteora parties”) for an over -the-counter Pursuant to the terms of the Forward Purchase Agreement, on the Closing Date, the Sellers purchased 425,606 shares of New Envoy Class A Common Stock (the “Recycled Shares”) directly from the redeeming stockholders of Anzu. Also on the Closing Date, the Company paid to the Sellers a prepayment amount of $4.5 million required under the Forward Purchase Agreement directly from the trust account and transferred to the Sellers 8,512 shares of New Envoy Class A Common Stock (the “Share Consideration”). In addition, pursuant to the subscription agreement, dated April 17, 2023 (as amended to date, the “Subscription Agreement”), by and between Anzu and Anzu SPAC GP I LLC (the “Sponsor”), the Company issued, and certain affiliates of the Sponsor purchased, concurrently with the Closing, an aggregate of 1,000,000 shares of the Company’s Series A preferred stock, par value $0.0001 per share (“Series A Preferred Stock”) in a private placement (the “PIPE Transaction”) at a price of $10.00 per share for an aggregate purchase price of $10 million. Pursuant to the convertible promissory note, dated April 17, 2023, between Envoy and GAT Funding, LLC (as amended to date, the “Envoy Bridge Note”), the Company issued 1,000,000 shares of the Company’s Series A Preferred Stock to GAT Funding, LLC in exchange for the conversion of the Envoy Bridge Note in full, concurrently with the Closing. The unaudited condensed consolidated financials include the accounts of Envoy Medical, Inc. and its wholly -owned Unaudited financial information The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and with the instructions to Form 10 -Q -01 -X www.sec.gov During the nine months ended September 30, 2023, there were no changes to the Company’s significant accounting policies as described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2022, which is included in the Proxy Statement/Prospectus. Restatement On December 14, 2023, the audit committee of the board of directors (the “Board”) of the Company, after considering the recommendations of management, concluded that the Company’s previously issued unaudited interim condensed consolidated financial statements included in the Company’s Quarterly Report on Form 10 -Q The Company reviewed its prior interpretation of the accounting guidance applicable to certain elements of the FPA and determined the prepayment amount of $2.4 million, previously recorded as forward purchase agreement assets in the condensed consolidated balance sheet, should be reclassified to the equity section of the condensed consolidated balance sheet, and the remaining liability balance associated with the FPA, including the the in -substance -current In accordance with Accounting Standards Codification (“ASC”) 250, Accounting Changes and Error Corrections, Description of error corrected: The previously reported Forward purchase agreement assets included a prepayment amount, as described above and in Note 3, Merger -substance -in Fair Value Measurement The effect of the correction of the error noted above on the relevant financial statement line items is as follows: As of September 30, 2023 As Previously Adjustments As Restated Condensed Consolidated Balance Sheet Forward purchase agreement assets 2,386 (2,386 ) — Total current assets 22,729 (2,386 ) 20,343 Total assets $ 23,601 $ (2,386 ) $ 21,215 FPA put option liability — 34 34 Forward purchase agreement warrant liability 1,793 (947 ) 846 Total current liabilities 13,603 (913 ) 12,690 Total liabilities $ 17,342 $ (913 ) $ 16,429 Additional paid-in capital 257,385 (1,473 ) 255,912 Total stockholders’ equity (deficit) $ 6,259 $ (1,473 ) $ 4,786 Total liabilities and stockholders’ equity (deficit) $ 23,601 $ (2,386 ) $ 21,215 Period Ended September 30, 2023 As Previously Adjustments As Restated Condensed Consolidated Statement of Stockholders’ Equity (Deficit) Meteora forward purchase agreement shares 89 (1,473 ) (1,384 ) Additional Paid-in Capital – balance at September 30, 2023 257,385 (1,473 ) 255,912 Total stockholders’ deficit – balance at September 30, 2023 $ 6,259 $ (1,473 ) $ 4,786 The change in accounting and related restatement for the FPA did not have any impact on the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, or net income (loss) attributable to common stockholders per share calculations for the three and nine month periods ended September 30, 2023 and 2022. As well, there was no impact on the condensed consolidated balance sheet or condensed consolidated equity statement for any prior reporting periods. Revision of Prior Period Financial Statements of Envoy During its financial close process for the three and nine months ended September 30, 2023, the Company discovered an error in Envoy’s accounting for convertible notes payable (related party) as of June 30, 2023. The convertible notes payable (related party) consists of convertible notes issued between 2012 and 2022 (the “Convertible Notes”) and the Envoy Bridge Note. When calculating the fair value of the Convertible Notes as of June 30, 2023, Envoy used an incorrect input in the valuation model related to the Convertible Notes settlement value upon a Merger with a Special Purpose Acquisition Company (“SPAC”). Specifically, the Business Combination Agreement includes the assumed exchange ratio of Envoy common stock, par value $0.01 per share (“Envoy Common Stock”) to New Envoy Class A Common Stock. The Business Combination Agreement also contains a provision that removed the holders’ right to redeem the Convertible Notes for its full principal and interest value upon the Closing, and instead forced the holders to convert the Convertible Notes into shares of Envoy Common Stock at a conversion rate of $1.00 per share, prior to the exchange into New Envoy Class A Common Stock. This assumed exchange ratio, the value of underlying Company stock, and the removal of the loan holders’ redemption right was not included under the SPAC scenario in the valuation model used to calculate the fair value of Convertible Notes as of June 30, 2023. The initial calculation calculated a fair value of approximately $51.4 million whereas the updated calculation, calculated a fair value of approximately $36.8 million, which results in a difference of approximately $14.6 million. The unaudited condensed consolidated statements of stockholders’ equity (deficit) for the three months ended June 30, 2023, has been revised to treat the Convertible Notes amendment, as described above, as an extinguishment of debt with a related party. As such, the impact of the amendment has been recorded as an additional deemed capital contribution from a related party on the revised unaudited condensed consolidated financial statements. The revision resulted in a downward adjustment of previously reported convertible notes payable (related party) of $14.6 million and an upward adjustment of $14.7 million in additional paid -in The Company also reassessed the components of cost of goods sold and determined that the costs related to the Acclaim product development and manufacturing of research and development (“R&D”) prototype parts for testing, validations and clinical trials should be classified as R&D expenses. Accordingly, $0.3 million of expenses previously included in the cost of goods sold have been reclassified to research and development for the nine months ended September 30, 2023. This reclassification did not impact net income.	1. Envoy Medical, Inc. (“Envoy Medical”, or the “Company”) was incorporated in the State of Delaware on December 28, 2020. The Company is focused on designing, developing and marketing fully implantable medical devices that improve hearing. The Company’s first commercial product, the Esteem PMA application, is a fully implantable hearing device. The Esteem PMA was cleared in 2010 by the United States Food and Drug Administration. The Company intends to continue to pursue development of a cochlear implant. Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and include the accounts of Envoy Medical, Inc. and its wholly -owned Emerging Growth Company Section 102(b)(1) of the Jumpstart Our Business Startups Act (“JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or no not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non -emerging Merger On September 29, 2023 (the “Closing Date”), a merger transaction between Envoy Medical, Anzu Special Acquisition Corp I (“Anzu”) and Envoy Merger Sub, Inc., a directly, wholly owned subsidiary of Anzu (“Merger Sub”) was completed (the “Merger” or “Business Combination” pursuant to the business combination agreement, dated as of April 17, 2023 (as amended, the “Business Combination Agreement”). In connection with the closing of the Merger (the “Closing”), Merger Sub merged with Envoy Medical, with Envoy Medical surviving the merger as a wholly owned subsidiary of Anzu. In connection with the Closing, Anzu changed its name to Envoy Medical, Inc. The Company’s Class A common stock, par value $0.0001 per share (“New Envoy Class A Common Stock”), and the Company’s warrants commenced trading on the Nasdaq Stock Market LLC (“Nasdaq”) on October 2, 2023 under the symbols “COCH” and “COCHW”, respectively. On April 17, 2023, prior to entering into the Business Combination Agreement, Anzu and Envoy Medical entered into an agreement (as amended to date, the “Forward Purchase Agreement” or “FPA”) with Meteora Special Opportunity Fund I, LP (“MSOF”), Meteora Capital Partners, LP (“MCP”), Meteora Select Trading Opportunities Master, LP (“MSTO”) and Meteora Strategic Capital, LLC (“MSC” and, collectively with MSOF, MCP and MSTO, the “Sellers” or “Meteora parties”) for an over -the-counter Pursuant to the terms of the Forward Purchase Agreement, on the Closing Date, the Sellers purchased 425,606 shares of New Envoy Class A Common Stock (the “Recycled Shares”) directly from the redeeming stockholders of Anzu. Also on the Closing Date, the Company paid to the Sellers a prepayment amount of $4.5 million required under the Forward Purchase Agreement directly from the trust account and transferred to the Sellers 8,512 In addition, pursuant to the subscription agreement, dated April 17, 2023 (as amended to date, the “Subscription Agreement”), by and between Anzu and Anzu SPAC GP I LLC (the “Sponsor”), the Company issued, and certain affiliates of the Sponsor purchased, concurrently with the Closing, an aggregate of 1,000,000 Pursuant to the convertible promissory note, dated April 17, 2023, between Envoy Medical and GAT Funding, LLC (as amended to date, the “Envoy Bridge Note”), the Company issued 1,000,000 Upon the Closing, the following occurred: • • • • • • • • • • • • • • • • • The proceeds received by the Company from the Merger, the PIPE Transaction, and the Forward Purchase Agreement, net of transaction costs, totaled $11.7 million. The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Anzu was treated as the acquired company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Anzu, accompanied by a recapitalization. The net assets of Anzu were stated at historical cost with no goodwill or other intangible assets recorded. The following table presents the total shares of New Envoy Class A Common Stock and Series A Preferred Stock outstanding immediately after the Closing: Class A Common Stock Number of Exchange of Anzu Class A Common Stock subject to possible redemption that was not redeemed for New Envoy Class A Common Stock 1,500,874 Conversion of Anzu Class B Common Stock held by the Sponsor and Anzu’s former independent director into New Envoy Class A Common Stock* 2,615,000 Subtotal – Merger, net of redemptions 4,115,874 Exchange of Envoy Common Stock for New Envoy Class A Common Stock 8,850,526 Exchange of Envoy Preferred Stock for New Envoy Class A Common Stock 1,272,055 Conversion of Convertible Notes as of September 29, 2023 into New Envoy Class A Common Stock 4,874,707 Net exercise of Envoy Warrants 2,702 Issuance of share consideration to Meteora parties 8,512 Shares recycled by Meteora parties 425,606 19,549,982 ____________ * shares of the New Envoy Class A Common Stock are unvested and subject to restrictions and forfeitures per the Sponsor Support Agreement. These shares will vest upon the FDA approval of Acclaim or upon a change of control of the Company (see Note 9) Series A Preferred Stock Number of Shares Exchange of Anzu Class B Common Stock for Series A Preferred Stock 2,500,000 Issuance of Series A Preferred Stock in connection with the PIPE Transaction 1,000,000 Issuance of Series A Preferred Stock in connection with the conversion of the Envoy Bridge 1,000,000 4,500,000 The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Going Concern Since inception, the Company has incurred cumulative losses from operations and has an accumulated deficit of $251.0 million at September 30, 2023. The Company has funded its operations and capital needs primarily through net proceeds from the issuances of convertible debt (see Note 9) and the sale of Envoy redeemable convertible preferred stock. In September 2023, the Company received $11.7 million proceeds from the Business Combination, Forward Purchase Agreement, and the PIPE Transaction, net of transaction costs. The Company had cash of $7.4 million as of September 30, 2023. Management believes that its existing cash balances combined with future capital raises, and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued. However, there can be no assurance that the Company will be successful in achieving its strategic plans, that the Company’s cash balances and future capital raises will be sufficient to support its ongoing operations, or that any additional financing will be available in a timely manner or on acceptable terms, if at all. If the Company is unable to raise sufficient financing when needed or events or circumstances occur such that the Company does not meet its strategic plans, the Company may be required to reduce certain discretionary spending, be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Company’s financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to the useful lives of property and equipment, inventory reserves, warranty liability, the fair value of common stock, the fair value of convertible notes payable, the fair value of forward purchase agreement assets, the fair value of forward purchase agreement warrant liability, the fair value of warrants and the outcome of litigation. Estimates and assumptions are reviewed periodically and the effect of changes, if any, are reflected in the unaudited condensed consolidated statements of operations and comprehensive income (loss). Concentration of Credit Risk and Significant Customers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and accounts receivable, net. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. There have been no material losses on accounts receivable. There were no customers that accounted for 10.0% or more of sales for the nine months ended September 30, 2023 and September 30, 2022, respectively. There were no customers that accounted for 10.0% or more of the accounts receivable balance as of September 30, 2023 and December 31, 2022. Cash and Restricted Cash The Company maintains cash balances in bank accounts which, at times, may exceed federally insured limits. Restricted cash is cash the Company holds for specific reasons and is not available for immediate use. Fair Value Measurement The Company determines the fair value of financial assets and liabilities using the fair value hierarchy established in ASC Topic 820, Fair Value Measurement • Level 1 • Level 2 • Level 3 A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company elected the fair value option for the convertible notes payable (related party) under ASC Topic 825, Financial Instruments, Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign -currency -valued at the end of each reporting period. Derivative liabilities are classified in the condensed consolidated balance sheets as current or non -current -cash The Company accounts for its warrant liability in accordance with ASC 815 -40 -measurement The Company accounts for its Forward Purchase Agreement in accordance with ASC 815 -40 -measurement Warrant Liability (Related Party) The Company classifies certain warrants issued to stockholders to purchase Envoy Common Stock (see Note 10) as a liability on its condensed consolidated balance sheets as these warrants are a free -standing SPAC Excise Tax Liability The Company recognizes excise tax as an incremental cost to repurchase the treasury shares, with an offsetting tax liability recognized. The SPAC excise tax liability was recorded in accrued expenses in the Company’s condensed consolidated balance sheets. Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers -step • • • • • Revenue is recognized as performance obligations under the terms of a contract are satisfied, which generally occurs as control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using either the expected value or most likely amount method. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information that is reasonably available. The Company primarily derives revenue from the sale of its hearing device products. Revenue from product sales is recognized upon transfer of control of the product to a customer, which occurs at a point in time, at the time the Company is notified the product has been implanted or used by the customer in a surgical procedure. The Company also sells extended warranty plans on a limited basis. Revenue from extended warranty plans is recognized ratably over time and is immaterial. Amounts received from a customer prior to fulfillment of the performance obligation are included as accrued expenses on the condensed consolidated balance sheets and are immaterial as of September 30, 2023 and December 31, 2022. The Company has elected to account for shipping and handling activities performed as activities to fulfill the promise to transfer the products, and therefore these activities are not assessed as a separate performance obligation to its customers. Revenue is measured as the amount of consideration the Company expects to receive, which is based on the invoiced price. The majority of the Company’s contracts have a single performance obligation and are short term in nature. The Company’s contracts do not include variable consideration. Payment terms differ by geography and customer, but payment is generally required within 30 days from the date of product utilization. The Company also offers extended payment plans on a limited basis. Amounts due to the Company under payment plans that extend beyond 12 months are immaterial as of September 30, 2023 and December 31, 2022, therefore the Company does not adjust the promised amount of consideration for the effects of a significant financing component. Segments Operating segments are identified as components of enterprise about which discrete financial information is available for evaluation by the chief operating decision -maker Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Effective In June 2016, the FASB issued ASU No. 2016 -13 Measurement of Credit Losses on Financial Instruments -13 Other than the item noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that have a significant impact, or potential significant impact, to our unaudited condensed consolidated financial statements.	2. Going Concern Since inception, the Company has incurred cumulative losses from operations and has an accumulated deficit of $226 million at December 31, 2022. The Company has funded its operations and capital needs primarily through net proceeds from the issuances of convertible debt (see Note 8) and the sale of preferred stock (see Note 10). The Company will need to raise additional funds to sustain its operations and to meet its long -term Management believes that its existing cash balances combined with future capital raises, and cash receipts from products will be sufficient to fund ongoing operations through at least one year from the date the consolidated financial statements are issued. However, there can be no assurance that the Company will be successful in achieving its strategic plans, that the Company’s cash balances and future capital raises will be sufficient to support its ongoing operations, or that any additional financing will be available in a timely manner or on acceptable terms, if at all. If the Company is unable to raise sufficient financing when needed or events or circumstances occur such that the Company does not meet its strategic plans, the Company may be required to reduce certain discretionary spending, be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Company’s financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the useful lives of property and equipment, inventory reserves, warranty liability, the fair value of common stock, the fair value of convertible notes payable, the fair value of warrants and the outcome of litigation. Estimates and assumptions are reviewed periodically and the effect of changes, if any, are reflected in the consolidated statements of operations and comprehensive loss. Concentration of Credit Risk and Significant Customers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and accounts receivable, net. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. There have been no material losses on accounts receivable. There were no customers that accounted for 10% or more of sales for the years ended December 31, 2022 and 2021, respectively. There were no customers that accounted for 10% or more of the accounts receivable balance as of December 31, 2022 and 2021. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents at December 31, 2022, and 2021. The Company maintains cash balances in bank accounts which, at times, may exceed federally insured limits. Accounts Receivable, Net of Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or other security to support amounts due. Accounts receivable are presented net of an allowance for doubtful accounts. Management performs ongoing credit evaluations of its customers based on financial information provided by the customer. Accounts receivable outstanding longer than the contractual payment terms are considered past due. The Company estimates its allowance for doubtful accounts by considering numerous factors, including delinquency trends along with ongoing customer credit evaluations. The Company writes off accounts receivable when they become uncollectible and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. The Company had no material bad debt expense and there were no material contract assets as of December 31, 2022 and 2021. The allowance for doubtful accounts was not material as of December 31, 2022 and 2021. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first -in -out -downs -down -down Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in operating results. Depreciation is calculated using the straight -line Operating Leases Effective January 1, 2022, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standard Update (“ASU”) No. 2016 -02 -effect -of-use -term -lease The Company leases its headquarters office space under an operating lease with a related party. The Company also leases office space in Germany under an operating lease (see Note 6). The determination of whether an arrangement is, or contains, a lease is performed at the inception of the arrangement and as necessary at modification. Operating leases are recorded on the consolidated balance sheets with operating lease assets representing the right to use the ROU asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. The Company excludes variable lease payments in measuring ROU assets and lease liabilities, other than those that depend on an index, a rate or are in -substance ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement date and exclude lease incentives. The discount rate implicit within the Company’s leases is generally not determinable; therefore, the Company determines the discount rate using its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Impairment of Long-Lived Assets Long -lived Fair Value Measurement The Company determines the fair value of financial assets and liabilities using the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”). ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The hierarchy describes three levels of inputs that may be used to measure fair value, as follows: • • • A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company elected the fair value option for the convertible notes payable (related party) (“Convertible Notes”) under ASC Topic 825, Financial Instruments, with changes in fair value recorded in loss from changes in fair value of convertible notes payable (related party) each reporting period. Redeemable Convertible Preferred Stock The Company recorded the redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The Company classifies its redeemable convertible preferred stock outside of stockholders’ deficit on the consolidated balance sheets because, in the event of certain “liquidation events” as defined in the agreement, that are not solely within the Company’s control, the shares would become redeemable at the option of the holders. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at either of the balance sheet dates. Subsequent adjustments to increase or decrease the carrying values to the ultimate liquidation values will be made only if and when it becomes probable that such a liquidation event will occur. Warrant Liability (Related Party) The Company classifies certain warrants to purchase common stock (see Note 9) as a liability on its consolidated balance sheets (included in accrued expenses) as these warrants are a free -standing Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, which provides a five -step • • • • • Revenue is recognized as performance obligations under the terms of a contract are satisfied, which generally occurs as control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using either the expected value or most likely amount method. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information that is reasonably available. The Company primarily derives revenue from the sale of its hearing device products. Revenue from product sales is recognized upon transfer of control of the product to a customer, which occurs at a point in time, at the time the Company is notified the product has been implanted or used by the customer in a surgical procedure. The Company also sells extended warranty plans on a limited basis. Revenue from extended warranty plans is recognized ratably over time and is immaterial. Amounts received from a customer prior to fulfillment of the performance obligation are included as accrued expenses on the consolidated balance sheets and are immaterial as of December 31, 2022 and 2021. The Company has elected to account for shipping and handling activities performed as activities to fulfill the promise to transfer the products, and therefore these activities are not assessed as a separate performance obligation to its customers. Revenue is measured as the amount of consideration the Company expects to receive, which is based on the invoiced price. The majority of the Company’s contracts have a single performance obligation and are short term in nature. The Company’s contracts do not include variable consideration. Payment terms differ by geography and customer, but payment is generally required within 30 days from the date of product utilization. The Company also offers extended payment plans on a limited basis. Amounts due to the Company under payment plans that extend beyond 12 months are immaterial as of December 31, 2022 and 2021, therefore the Company does not adjust the promised amount of consideration for the effects of a significant financing component. Cost of Goods Sold Cost of goods sold is comprised of the costs of merchandise sold, as well as the related inbound freight costs and labor directly attributable to bringing certain goods to a saleable condition. In categorizing costs, the Company captures applicable depreciation and costs to maintain and run revenue generating technology, equipment related costs and any personnel -related Product Warranty The Company provides a limited warranty for implantable components. At the time product revenue is recognized, the Company reserves for estimated future costs that may be incurred under its warranties based on historical experience. The limited warranty liability is recorded in accrued expenses in the consolidated balance sheets. As of December 31, 2022 and 2021, the amount of accrued limited warranty was immaterial and the Company’s warranty payments were immaterial. During 2013, the Company offered a lifetime warranty to clinical trial patients to cover battery and surgery related costs. The Company estimates the costs that may be incurred under this lifetime warranty and records a liability in the amount of such costs at its present value. The lifetime warranty is recorded in warranty liability in the consolidated balance sheets. As of December 31, 2022 and 2021, warranty liability was $2.5 million and $3.0 million, respectively, of which $0.3 million and $0.2 million, respectively, was classified as a current liability in the consolidated balance sheets. Patents All patent -related Research and Development Costs Expenditures for research and development activities are charged to operations as incurred. Research and development costs include salaries, employee benefits and laboratory testing expenses. Stock-Based Compensation The cost of employee and non -employee -Scholes -pricing Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company has recorded a full valuation allowance against the net deferred tax asset due to the uncertainty of realizing the related benefits. The Company recognizes the financial statement benefit of a tax position only to the extent the position is more likely than not to be sustained upon audit based on the technical merits of the position. For tax positions meeting the more -likely-than-not Foreign Currency Translation The Euro is the functional currency for the Company’s foreign subsidiary in Germany and the Brazilian Real is the functional currency of the Company’s subsidiary in Brazil. The assets and liabilities of the Company’s foreign operations are translated into U.S. dollars at the end -of-the-period -average Net Loss per Share The Company applies the two -class -class -class Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted -average -average -converted -dilutive Segments Operating segments are identified as components of enterprise about which discrete financial information is available for evaluation by the chief operating decision -maker Recently Adopted Accounting Pronouncements Effective January 1, 2022, the Company adopted Topic 842. The Company utilized the effective date transition method set forth in ASU No. 2018 -11 -effect In August 2020, the FASB issued ASU No. 2020 -06 -20 -40 -06 -per-share -converted-method -06 Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016 -13 -13 -13 -for-sale -13

Fair Value Measurement

Fair Value Measurement	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Fair Value Measurement [Abstract]
Fair Value Measurement	4. The following tables provide information related to the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands): September 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Forward purchase agreement warrant liability $ — $ — $ 846 $ 846 FPA put option liability 34 34 Warrant liability 1,274 — — 1,274 $ 1,274 $ — $ 880 $ 2,154 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable, net of current portion $ — $ — $ 33,397 $ 33,397 Convertible notes payable, current portion (related party) — — 448 448 Warrant liability (related party) — — 127 127 $ — $ — $ 33,972 $ 33,972 The fair values of the FPA put option liability and the forward purchase agreement warrant liability were estimated using Monte Carlo Simulation models, which are Level 3 fair value measurement. The following table presents the quantitative information regarding Level 3 fair value measurements of the forward purchase agreement assets and forward purchase agreement warrant liability: September 30, 2023 Stock price $ 5.64 Initial exercise price 10.46 Remaining term (in years) 1.00 Risk-free rate 5.32 % The fair value of the Convertible Notes was based on a probability -weighted The significant inputs that were used in the valuation of the Convertible Notes are presented below (in thousands, except per share amounts): December 31, 2022 Share price $ 0.33 Discount rate 14.8 % Volatility 91.0 % Probability of qualified financing 5.0 % Probability of SPAC/IPO 25.0 % Probability of default 60.0 % Probability of held to maturity 10.0 % Recovery upon default (2012 and 2013 Convertible Notes) $ 10,000 Significant judgment is required in selecting the inputs. On December 31, 2022, an evaluation was performed to assess those inputs and general market conditions potentially affecting the fair value of the Convertible Notes. Should the probability of default increase or decrease by 5.0%, the fair value of the Convertible Notes on December 31, 2022 could decrease or increase by $2.6 million, respectively. Should the discount rate increase or decrease by 5.0%, the fair value of the Convertible Notes could decrease by $1.5 million or increase by $1.6 million, respectively. The fair value of the Convertible Notes is subject to variation should the expected future cash flows vary significantly from the estimates. Effective concurrently with the Merger, the outstanding balance of principal and accrued interest of the Convertible Notes was automatically converted into New Envoy Class A Common Stock and the outstanding balance of principal and accrued interest of the Envoy Bridge Note was converted into Series A Preferred Stock (see Note 3). As such, the Convertible Notes and Envoy Bridge Note were derecognized from the condensed consolidated balance sheet. Immediately prior to the Merger, the fair value of the Convertible Notes was calculated by the multiplying the amount of New Envoy Class A Common Stock the Convertible Notes converted into by the fair value of these shares. The fair value of the New Envoy Class A Common Stock was based on the listed prices for the shares, immediately prior to the Merger. Immediately prior to the Merger, the fair value of the Envoy Bridge Note was calculated by multiplying the amount of Series A Preferred Stock the Envoy Bridge Note converted into, by the fair value of these shares. The fair value of the Series A Preferred Stock was estimated using a Monte Carlo Simulation model, which is a Level 3 fair value measurement. The following table presents the quantitative information regarding Level 3 fair value measurements of the Series A Preferred Stock, which was valued at $10.98 per share. September 30, 2023 Underlying stock price 7.02 Exercise price 11.50 Expected term (in years) 10.00 Expected volatility 48.9 % The Company has classified the warrant liability within Level 1 of the hierarchy as the warrant liability is separately listed and traded in an active market. The warrant liability’s listed price in an active market was used as the fair value. The Company has classified the warrants (related party) within Level 3 of the hierarchy as the fair value is derived using the Black -Scholes -free -party -free -specific The following table presents the unobservable inputs of the warrant liability (related party): December 31, 2022 Risk-free interest rate 3.9 % Expected dividend yield 0.0 % Expected term (in years) 9.5 Expected volatility 62.8 % The following table summarizes the activity for the Company’s Level 3 instruments measured at fair value on a recurring basis (in thousands): Convertible Warrant FPA Put Forward Balance as of December 31, 2022 $ 33,845 $ 127 $ — $ — Issuances 2,048 — — — Change in fair value 9,377 104 — — Balance as of March 31, 2023 $ 45,270 $ 231 $ — $ — Issuances 1,964 — — — Change in fair value 8,857 — — — Capital contribution (14,678 ) — — — Balance as of June 30, 2023 $ 41,413 $ 231 $ — $ — Issuances 1,964 — $ 34 $ 846 Change in fair value (4,902 ) — — — Conversion (38,475 ) (231 ) — — Balance as of September 30, 2023 $ — $ — $ 34 $ 846 There were no transfers between Level 1 and Level	3. The following tables provide information related to the Company’s liabilities measured at fair value on a recurring basis as of December 31, 2022 and December 31, 2021 (in thousands): December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable, net of current portion $ — $ — $ 33,397 $ 33,397 Convertible notes payable, current portion (related party) — — 448 448 Warrant liability (related party) — — 127 127 $ — $ — $ 33,972 $ 33,972 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable, net of current portion $ — $ — $ 23,477 $ 23,477 $ — $ — $ 23,477 $ 23,477 The fair value of the Convertible Notes was based on a probability -weighted -purpose The significant inputs that were used in the valuation of the Convertible Notes include (in thousands, except per share amounts): December 31, 2022 2021 Share price $ 0.33 $ 0.29 Discount rate 14.8 % 13.9 % Volatility 91.0 % 85.0 % Probability of qualified financing 5.0 % 10.0 % Probability of SPAC/IPO 25.0 % 0 % Probability of default 60.0 % 70.0 % Probability of held to maturity 10.0 % 20.0 % Recovery upon default $ 10,000 $ 10,000 Significant judgment is required in selecting the significant inputs. At December 31, 2022, an evaluation was performed to assess those inputs and general market conditions potentially affecting the fair market value of the Convertible Notes. Should the probability of default increase or decrease by 5.0%, the fair value of the Convertible Notes could decrease or increase by $2.6 million, respectively. Should the discount rate increase or decrease by 5.0%, the fair value of the Convertible Notes could decrease by $1.5 million or increase by $1.6 million, respectively. The fair value of the Convertible Notes is subject to variation should the expected future cash flows vary significantly from the estimates. The Company has classified the warrants within Level 3 of the hierarchy as the fair value is derived using the Black -Scholes -free -party -free 0% -specific The following table presents the unobservable inputs of the warrant liability: December 31, 2022 2021 Risk-free interest rate 3.9 % Not applicable Expected dividend yield 0.0 % Not applicable Expected term (in years) 9.5 Not applicable Expected volatility 62.8 % Not applicable The following table summarizes the activity for the Company’s Level 3 instruments measured at fair value on a recurring basis (in thousands): Convertible Warrant Balance as of December 31, 2020 $ 18,870 $ — Issuances 2,859 — Change in fair value 1,748 — Balance as of December 31, 2021 23,477 — Issuances 3,278 92 Change in fair value 7,090 35 Balance as of December 31, 2022 $ 33,845 $ 127 During the years ended December 31, 2022, and 2021, there were no transfers between Level 1 and Level 2, nor into and out of Level 3.

Balance Sheet Details - Current

Balance Sheet Details - Current Assets and Current Liabilities	12 Months Ended
	Dec. 31, 2022
Balance Sheet Details - Current Assets and Current Liabilities [Abstract]
Balance Sheet Details - Current Assets and Current Liabilities	4. Inventories Inventories, consisted of the following (in thousands): December 31, 2022 2021 Raw materials $ 1,010 $ 811 Work-in-progress 164 112 Finished goods 121 137 $ 1,295 $ 1,060 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2022 2021 Prepaid maintenance fees and subscriptions $ 73 $ 85 Prepaid insurance 21 21 Other prepaid expenses 35 61 $ 129 $ 167 Accrued Expenses Accrued expenses consisted of the following (in thousands): December 31, 2022 2021 Inventory purchased not invoiced $ 210 $ 7 Professional fees 168 56 Payroll and benefits 96 117 Accrued warranty reserve 43 54 Accrued clinical expenses 17 16 Contract liabilities 15 15 Taxes payable 6 54 Deferred rent — 131 Other 53 25 $ 608 $ 475

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property and Equipment, Net [Abstract]
Property and Equipment, Net	5. Property and equipment, net, consisted of the following (in thousands): December 31, 2022 2021 Office equipment $ 754 $ 602 Research and development equipment 4,106 4,043 4,860 4,645 Less: Accumulated depreciation (4,529 ) (4,457 ) $ 331 $ 188 Depreciation expense was $75 thousand and $71 thousand for the years ended December 31, 2022 and 2021, respectively.

Operating Leases

Operating Leases	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Operating Leases [Abstract]
Operating Leases	7. The Company leases its headquarters office space in Minnesota and leases office space in Germany. The lease for the Company’s headquarters office space expires at the end of 2027. This headquarters office space lease is with a stockholder, which is considered a related party. The lease of the office space in Germany is not with a related party and is immaterial. The components of leases and lease costs were as follows (in thousands): September 30, December 31, Operating lease right-of-use assets (related party) $ 494 $ 577 Operating lease liability, current portion (related party) $ 149 $ 125 Operating lease liabilities, net of current portion (related party) 440 565 $ 589 $ 690 Nine Months Ended 2023 2022 Operating lease cost $ 97 $ 97 $ 97 $ 97 Other supplemental information of lease amounts recognized in the unaudited condensed consolidated financial statements is summarized as follows: Nine Months Ended 2023 2022 Cash paid for amounts included in the measurement of lease liabilities $ 113 $ 111 September 30, December 31, Weighted-average remaining lease term – in years 4.2 4.9 Weighted-average discount rate 5.0 % 5.0 % Future minimum lease payments associated with these leases were as follows on September 30, 2023 (in thousands): Amount 2023 (remaining) $ 28 2024 162 2025 154 2026 155 2027 99 598 Less: Imputed interest (9 ) $ 589	6. The Company leases its headquarters office space in Minnesota and leases office space in Germany. The lease for the Company’s headquarters office space expires at the end of 2027. This headquarters office space lease is with a stockholder, which is considered a related party. The lease of the office space in Germany is not with a related party and is immaterial. The components of leases and lease costs were as follows (in thousands): December 31, 2022 Operating lease right-of-use assets (related party) $ 577 Operating lease liability, current portion (related party) $ 125 Operating lease liabilities, net of current portion (related party) 565 $ 690 December 31, 2022 Operating lease cost $ 124 $ 124 Prior to the adoption of Topic 842 on January 1, 2022, the Company recognized rent expense on a straight -line Other supplemental information of lease amounts recognized in the consolidated financial statements is summarized as follows: December 31, 2022 Cash paid for amounts included in the measurement of lease liabilities $ 138 Right-of-use assets obtained in exchange for new operating lease obligations $ 696 Weighted-average remaining lease term – in years 4.9 Weighted-average discount rate 5.0 % Future minimum lease payments associated with these leases were as follows on December 31, 2022 (in thousands): Amount 2023 $ 140 2024 161 2025 153 2026 153 2027 97 704 Less: Imputed interest (14 ) $ 690 Future minimum lease payments associated with these leases were as follows on December 31, 2021 (in thousands): Amount 2022 $ 141 2023 140 2024 161 2025 153 2026 153 2027 97 $ 845

Product Warranty Liability

Product Warranty Liability	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Warranty Liability [Abstract]
Product Warranty Liability	8. Changes in warranty liability were as follows (in thousands): Amount Balance as of December 31, 2022 $ 2,478 Utilization (62 ) Balance as of March 31, 2023 $ 2,416 Reversal of product warranty accrual (45 ) Utilization (25 ) Balance as of June 30, 2023 $ 2,346 Reversal of product warranty accrual (72 ) Utilization (21 ) Balance as of September 30, 2023 $ 2,253 The assumptions utilized in developing the liability as of September 30, 2023, include an estimated cost per unit of $6 thousand, an average battery life of 5 -2012	7. Changes in warranty liability were as follows (in thousands): December 31, 2022 2021 Balance at beginning of the year $ 2,998 $ 3,166 Reversal of warranty accrual (456 ) (65 ) Utilization (64 ) (103 ) Balance at end of the year $ 2,478 $ 2,998 The assumptions utilized in developing the liability as of December 31, 2022 and 2021 include an estimated cost per unit of $6 thousand, an average battery life of 5 -2012

Convertible Notes Payable (Rela

Convertible Notes Payable (Related Party)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Convertible Notes Payable (Related Party) [Abstract]
Convertible Notes Payable (Related Party)	9. The Company received several loan financings from stockholders from 2012 to 2023, in an aggregate outstanding principal amount of $59.7 million as of December 31, 2022. The Company elected the fair value option for the Convertible Notes and the Envoy Bridge Note under ASC Topic 825, Financial Instruments, 2012 Convertible Note In 2012, the Company issued a convertible note to a stockholder (“2012 Convertible Note”), which was subsequently amended and restated. These amendments allowed for the issuance of additional principal under the existing agreements and resulted in various drawdowns since 2012. In March 2021, the 2012 Convertible Note agreement was amended and restated to allow for an additional draw of $10.0 million. The March 2021 amendment also extended the maturity date of both the existing debt and any future draws to December 31, 2025. In June 2022, the 2012 Convertible Note agreement was amended and restated to allow for an additional draw of $10.0 million. These amendments were accounted for as debt modifications. On April 17, 2023, the drawdowns that were made in 2023 with an aggregate principal amount of $4.0 million were transferred to another convertible note with the same stockholder, refer to the Envoy Bridge Note disclosure below. The outstanding principal amount of the 2012 Convertible Note was $59.0 million as of December 31, 2022. Undrawn principal under the arrangement amounted to $5.0 million as December 31, 2022. The 2012 Convertible Note would have matured on December 31, 2025, and was classified as a long -term At any time prior to maturity, at the sole discretion of the noteholder, the outstanding principal amount plus accrued and unpaid interest may have been converted into shares of Envoy Common Stock at a conversion price of $1.00 per share, subject to various adjustments as defined in the 2012 Convertible Note agreement. In the event that the Company obtained additional equity financing pursuant to which the Company sold shares of either common or preferred stock, at the sole discretion of the stockholder, the principal amount plus accrued and unpaid interest would convert to the class of stock being offered in the financing at a price per share equal to 80% of the price per share paid by investors for the offered shares. On April 17, 2023, the 2012 Convertible Note was amended as part of the Business Combination Agreement, to provide for automatic conversion immediately prior to the Merger. The conversion formula was not adjusted as part of this amendment. The loan amendment was accounted for as an extinguishment with a related party and treated as a deemed capital contribution. Effective concurrently with the Merger, the outstanding balance of principal and any unpaid accrued interest was automatically converted into New Envoy Class A Common Stock at a conversion price of $15.72 per share (see Note 3) and the fair value of the 2012 Convertible Notes was derecognized from the condensed consolidated balance sheets. 2013 Convertible Notes In 2013, the Company issued convertible notes to various stockholders (“2013 Convertible Notes”), which were subsequently amended and restated. The outstanding principal amount of these notes was $0.7 million as of December 31, 2022. The 2013 Convertible Notes mature on December 31, 2023, and were classified as current liabilities as of December 31, 2022. The 2013 Convertible Notes bore interest at 4.5% per annum. The 2013 Convertible Notes were secured by the Company’s assets. The Company granted detachable common stock warrants to the noteholders in connection with the issuance of the 2013 Convertible Notes (see Note 10). The 2013 Convertible Notes were subordinated to the 2012 Convertible Note and included the same conversion features as the 2012 Convertible Note. In addition, in the event the Company completed an equity financing in which it sold a minimum of $2,500,000 of new stock, at the sole discretion of the Company, the principal amount plus accrued and unpaid interest would convert into Envoy Common Stock at $1.00 per share. If the effective conversion price was less than $1.00, the price per share shall be equal to 80% of the price per share paid by the other investors. On April 17, 2023, the 2013 Convertible Notes were amended as part of the Business Combination Agreement to provide for automatic conversion immediately prior to the Merger. The conversion formula was not adjusted as part of this amendment. The loan amendment was accounted for as an extinguishment with a related party and treated as a deemed capital contribution. Effective concurrently with the Merger, the outstanding balance of principal and any unpaid accrued interest was automatically converted into New Envoy Class A Common stock at a conversion price of $15.72 per share and the fair value of the 2013 Convertible Notes was derecognized from the condensed consolidated balance sheets (see Note 3). Envoy Bridge Note (“2023 Convertible Note”) On April 17, 2023, the Company entered into a convertible promissory note agreement with a stockholder for an aggregate borrowing capacity of $10.0 million, an interest rate of 4.5% per annum and maturity date of December 31, 2025. The Envoy Bridge Note was unsecured. According to this agreement, $4.0 million of the borrowing capacity was funded via the transfer of $4.0 million in principal from the 2012 Convertible Note. An additional $3.0 million was drawn upon during the second quarter of 2023 and $3.0 million was drawn upon during the third quarter of 2023. The transfer of $4.0 million in principal from the 2012 Convertible Note to the Envoy Bridge Note was accounted for as a debt modification. The difference between the proceeds received and the issuance -date The Company could have prepaid the Envoy Bridge Note in whole or in part without premium or penalty. Contingent upon, and effective concurrently with the Merger, the outstanding balance of principal and any unpaid accrued interest, automatically converted to Series A Preferred Stock at a conversion price of $10.00 per share. If the Business Combination Agreement terminated pursuant to its terms, at the sole discretion of the noteholder, the outstanding principal amount plus accrued and unpaid interest could have been converted into shares of Envoy Common Stock at a conversion price of $1.00 per share, subject to various adjustments as defined in the agreement. If the Business Combination Agreement terminated pursuant to its terms and in the event that the Company obtained additional equity financing pursuant to which the Company sold shares of either common or preferred stock, at the sole discretion of the noteholder, the principal amount plus accrued and unpaid interest would have converted to the class of stock being offered in the financing at a price per share equal to 80% of the price per share paid by investors for the offered shares. On August 23, 2023, the Envoy Bridge Note was amended pursuant to which the Company could have drawn an additional $5.0 million if the Company had less than $5.0 million in cash or net tangible assets immediately following the Merger. In addition, the Company could have drawn up to $2.0 million if the Merger did not occur by September 30, 2023. Effective concurrently with the Merger, the outstanding balance of principal and any unpaid accrued interest, was automatically converted to Series A Preferred Stock at a conversion price of $10.00 per share and the fair value of the Envoy Bridge Note was derecognized from the condensed consolidated balance sheets.	8. The Company received several loan financings from stockholders from 2012 to 2022, in an aggregate outstanding principal amount of $59.7 million and $51.7 million as of December 31, 2022 and December 31, 2021, respectively. The Convertible Notes bear interest at 4.5% per annum. The Convertible Notes are secured by the Company’s assets. The Company elected the fair value option for the Convertible Notes under ASC Topic 825, Financial Instruments, with changes in fair value recorded in earnings each reporting period. The Convertible Notes did not include any financial covenants and were subject to acceleration upon the occurrence of specified events of default. The terms of the Convertible Notes are described below. 2012 Convertible Note In 2012, the Company issued a convertible note to a stockholder (“2012 Convertible Note”), which was subsequently amended and restated. These amendments allowed for the issuance of additional principal under the existing agreements and resulted in various drawdowns since 2012. In March 2021, the 2012 Convertible Note agreement was amended and restated to allow for an additional draw of $10.0 million. The March 2021 amendment also extended the maturity date of both the existing debt and any future draws to December 31, 2025. In June 2022, the 2012 Convertible Note agreement was amended and restated to allow for an additional draw of $10.0 million. These amendments were accounted for as debt modifications. The Company elected the fair value option for the Convertible Notes. The Company received proceeds of $8.0 million from the issuance of the 2012 Convertible Note in each of the years ended December 31, 2022 and 2021. The fair value of the 2012 Convertible Note on the date of issuance was $3.3 million and $2.9 million on the respective drawdown dates in 2022 and 2021, respectively. The difference between the proceeds received and the issuance -date The outstanding principal amount of the 2012 Convertible Note was $59.0 million and $51.0 million as of December 31, 2022 and December 31, 2021, respectively. Undrawn principal under the arrangement amounted to $5 million and $3 million as of December 31, 2022, and 2021, respectively. The 2012 Convertible Note matures on December 31, 2025, and was classified as a long -term At any time prior to maturity, at the sole discretion of the noteholder, the outstanding principal amount plus accrued and unpaid interest may be converted into shares of common stock at a conversion price of $1.00 per share, subject to various adjustments as defined in the agreement. In the event that the Company obtains additional equity financing pursuant to which the Company sells shares of either common or preferred stock, at the sole discretion of the stockholder, the principal amount plus accrued and unpaid interest will convert to the class of stock being offered in the financing at a price per share equal to 80% of the price per share paid by investors for the offered shares. 2013 Convertible Notes In 2013, the Company issued convertible notes to various stockholders (“2013 Convertible Notes”), which were subsequently amended and restated. The outstanding principal amount of these notes were $0.7 million and $0.7 million as of December 31, 2022 and December 31, 2021, respectively. The 2013 Convertible Notes mature on December 31, 2023, and were classified as current liabilities as of December 31, 2022 and non -current December 31, 2021. The 2013 Convertible Notes bear interest at 4.5% per annum. The Company granted detachable common stock warrants to the noteholders in connection with the issuance of the 2013 Convertible Notes (see Note 9). The 2013 Convertible Notes are subordinated to the 2012 Convertible Note and include the same conversion features as the 2012 Convertible Note. In addition, in the event the Company completes an equity financing in which it sells a minimum of $2,500,000 of new stock, at the sole discretion of the Company, the principal amount plus accrued and unpaid interest will convert into common stock at $1.00 per share. If the effective conversion price is less than $1.00, the price per share shall be equal to 80% of the price per share paid by the other investors. In November 2021, a holder of the 2013 Convertible Notes surrendered their convertible note payable of $50 thousand, as well as accrued interest of $18 thousand, which was treated as a capital contribution given the related party nature of the debt.

Common Stock and Redeemable Con

Common Stock and Redeemable Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2022
Redeemable Convertible Preferred Stock [Abstract]
Common Stock and Redeemable Convertible Preferred Stock	9. As of December 31, 2022 and 2021, the Company was authorized to issue 400,000,000 Redeemable Convertible Preferred Stock As of December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 10,000,000 During 2015, the Company issued and sold 2,000,000 During 2017, the Company issued and sold 2,000,000 As described in Note 1, in connection with the Merger, each share of Envoy redeemable convertible preferred stock, par value $0.01 per share, issued and outstanding immediately prior to the Closing, which totaled 4,000,000 Contingent Sponsor Shares Pursuant to the Sponsor Support Agreement, 1,000,000 The Contingent Sponsor Shares meets the definition of a derivative, but meets the criteria to be considered indexed to the Company’s stock and the equity -classification Common Stock Warrants (Related Party) Between November 2013 and July 2022, the Company issued warrants to purchase shares of Envoy Common Stock to stockholders in connection with the issuance of the Convertible Notes and the issuance of Envoy Preferred Stock. In July 2022, the Company issued a warrant to purchase 1,150,000 On April 17, 2023, the common stock warrants were amended to provide for automatic cashless exercise or cancellation of the warrants immediately prior to the Merger. On September 29, 2023, the warrants were canceled or converted on a net exercise basis into shares of New Envoy Class A Common Stock. Out of the 8,695,000 warrants outstanding prior to the Merger, 70,000 were converted into 2,702 -months The following table summarizes the Company’s outstanding common stock warrants as of December 31, 2022: Year of issue Numbers of Shares Issuable Exercise Price Expiration Date Classification 2013 70,000 $ 0.25 Nov – 2023 Equity 2015 2,300,000 $ 1.00 Nov – 2025 Equity 2017 2,300,000 $ 1.00 Aug – 2027 Equity 2018 805,000 $ 1.00 Jan – 2029 Equity 2019 920,000 $ 1.00 Dec – 2029 Equity 2021 1,150,000 $ 1.00 Dec – 2030 Equity 2022 1,150,000 $ 1.00 July – 2032 Liability 8,695,000

Series A Preferred Stock

Series A Preferred Stock	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Series A Preferred Stock [Abstract]
Series A Preferred Stock	11. As of September 30, 2023, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 100,000,000 shares of $0.0001 par value preferred stock, of which 10,000,000 shares have been designated as Series A Preferred Stock. Pursuant to the Envoy Bridge Note, the Sponsor Support Agreement and the Subscription Agreement, the Company issued an aggregate of 4,500,000 shares of Series A Preferred Stock (see Note 3) as of September 30, 2023. Pursuant to the Subscription Agreement and the Envoy Bridge Note, the Sponsor and GAT Funding, LLC each contributed additional $1.0 million capital contribution to subscribe for additional shares of Series A Preferred Stock at a price of $10.00 per share in order to meet the net tangible assets requirement under the Business Combination Agreement (see Note 3). As of September 30, 2023, the Sponsor’s contribution is classified as other receivables on the condensed consolidated balance sheets. The holders of the Series A Preferred Stock has the following rights and preferences: Voting rights The holders of the Series A Preferred Stock are not entitled to vote or receive notice of any meeting of stockholders, except in the case that the Company creates any equity or debt instrument that ranks senior or pari passu to the rights of the Series A Preferred Stock or in the case of any adverse change to the powers, preferences or special rights of the Series A Preferred Stock. Conversion rights Each share of Series A Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into such number of shares of New Envoy Class A Common Stock as determined by dividing the issuance price of the shares of Series A Preferred Stock of $10.00, by the conversion price, which was $11.50 per share as of September 30, 2023 and is adjustable for certain dilutive events. At any time from and after 90 days following the Merger, if the closing price per share of New Envoy Class A Common Stock is greater than $15.00 for any twenty trading days within a period of thirty trading days, the Company may elect, in its discretion, to convert all, but not less than all, of the then outstanding shares of Series A Preferred Stock into shares of New Envoy Class A Common Stock. In this case, each share of Series A Preferred Stock then outstanding shall be converted into the number of shares of New Envoy Class A Common Stock equal to the quotient of i) $10.00 divided by ii) $15.00. Redemption The holders of Series A Preferred Stock are not entitled to any redemption rights, other than those under their liquidation rights discussed below. The Company does not have the option to redeem the Series A Preferred Stock. Dividend Rights The holders of Series A Preferred Stock are entitled to a cumulative dividend which accrues at the rate of 12% of the original issuance price of $10.00 per annum. The dividend accrues on a daily basis from and including the issuance date of such shares, whether or not declared, and will be payable in cash on a quarterly basis. With respect to the first four (4) dividends, the Company shall maintain the funds allocated for such dividends in a separate account. If the Company fails to pay the dividends on the dividend payment date, then an additional dividend on the amount of the unpaid portion shall automatically accrue at 12%. There were no dividends declared as of September 30, 2023. As the Company is required to maintain the funds allocated for the first four dividend payments in a separate account, $5.4 million of the Company’s cash has been reclassed to restricted cash (see Note 5). Pursuant to the Sponsor Support Agreement, any dividends arising shall accrue and not require timely payment at any time when the Company has less than $10 million of net tangible assets. Liquidation preference In the event of any liquidation, deemed liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holder of the Series A Preferred Stock is entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of any security of the Company that ranks junior to the Series A Preferred Stock, including, but not limited to, the New Envoy Class A Common Stock, an amount per share of Series A Preferred Stock equal to the greater of i) $10.00 plus any unpaid cash dividends and ii) the amount the holder would have received, would such holder, immediately prior to such involuntary liquidation, dissolution or winding up of Company, converted such share of Series A Preferred Stock into New Envoy Class A Common Stock.	10. As of the Closing, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 100,000,000 Pursuant to the Envoy Bridge Note, the Sponsor Support Agreement and the Subscription Agreement, the Company issued an aggregate of 4,500,000 Pursuant to the Subscription Agreement and the Envoy Bridge Note, the Sponsor and GAT Funding, LLC each contributed additional $1.0 million capital contribution to subscribe for additional shares of Series A Preferred Stock at a price of $10.00 per share in order to meet the net tangible assets requirement under the Business Combination Agreement. The holders of the Series A Preferred Stock has the following rights and preferences: Voting rights The holders of the Series A Preferred Stock are not entitled to vote or receive notice of any meeting of stockholders, except in the case that the Company creates any equity or debt instrument that ranks senior or pari passu to the rights of the Series A Preferred Stock or in the case of any adverse change to the powers, preferences or special rights of the Series A Preferred Stock. Conversion rights Each share of Series A Preferred Stock shall be convertible, at the option of the holder, at any time after the date of issuance into such number of shares of New Envoy Class A Common Stock as determined by dividing the issuance price of the shares of Series A Preferred Stock of $10.00, by the conversion price, which was $11.50 per share as of the Closing and is adjustable for certain dilutive events. At any time from and after 90 days following the Merger, if the closing price per share of New Envoy Class A Common Stock is greater than $15.00 for any twenty trading days within a period of thirty trading days, the Company may elect, in its discretion, to convert all, but not less than all, of the then outstanding shares of Series A Preferred Stock into shares of New Envoy Class A Common Stock. In this case, each share of Series A Preferred Stock then outstanding shall be converted into the number of shares of New Envoy Class A Common Stock equal to the quotient of i) $10.00 divided by ii) $15.00. Redemption The holders of Series A Preferred Stock are not entitled to any redemption rights, other than those under their liquidation rights discussed below. The Company does not have the option to redeem the Series A Preferred Stock. Dividend Rights The holders of Series A Preferred Stock are entitled to a cumulative dividend which accrues at the rate of 12% of the original issuance price of $10.00 per annum. The dividend accrues on a daily basis from and including the issuance date of such shares, whether or not declared, and will be payable in cash on a quarterly basis. With respect to the first four (4) dividends, the Company shall maintain the funds allocated for such dividends in a separate account. If the Company fails to pay the dividends on the dividend payment date, then an additional dividend on the amount of the unpaid portion shall automatically accrue at 12%. Pursuant to the Sponsor Support Agreement, any dividends arising shall accrue and not require timely payment at any time when the Company has less than $10 million of net tangible assets. Liquidation preference In the event of any liquidation, deemed liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holder of the Series A Preferred Stock is entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of any security of the Company that ranks junior to the Series A Preferred Stock, including, but not limited to, the New Envoy Class A Common Stock, an amount per share of Series A Preferred Stock equal to the greater of i) $10.00 plus any unpaid cash dividends and ii) the amount the holder would have received, would such holder, immediately prior to such involuntary liquidation, dissolution or winding up of Company, converted such share of Series A Preferred Stock into New Envoy Class A Common Stock.

Stock Options

Stock Options	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Stock Options [Abstract]
Stock Options	12. The Company had a stock incentive plan (the “2003 Stock Option Plan”) that provided for the granting of stock options or other stock incentives to employees, officers, directors and consultants. The 2003 Stock Option Plan was administered by the Board, or a committee designated by the Board, which determined the persons who were to receive awards under the 2003 Stock Option Plan, the number of shares subject to each award and the term and exercise price of each award. The maximum term of options granted under the 2003 Stock Option Plan was ten years. The number of shares of Envoy Common Stock authorized to be issued was 6,400,000 under the 2003 Stock Option Plan. In March 2013, the Company and its stockholders adopted a new plan (the “2013 Stock Option Plan”) on substantially the same terms and conditions of the 2003 Stock Option Plan. The Company and its stockholders reserved a total of 7,000,000 shares of Envoy Common Stock for issuance under the 2013 Stock Option Plan and reduced the number of shares of Envoy Common Stock available for issuance under the 2003 Stock Option Plan from 6,400,000 to 552,000. As of April 2013, the 2003 Stock Option Plan expired and no further stock options or shares may be granted under that plan. On April 17, 2023, the Company and the stock option holders agreed that the stock options will be cancelled and terminated for no consideration upon the Merger. The Company uses the Black -Scholes Immediately before the Merger and as of December 31, 2022, all stock options outstanding were fully vested and there was no unrecognized stock -based The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2023: Options Weighted- Weighted- Intrinsic Value Outstanding at December 31, 2022 263,000 $ 1.25 1.01 $ — Outstanding at September 30, 2022 — n/a n/a n/a Exercisable and vested at September 30, 2023 — n/a n/a n/a The aggregate intrinsic value of stock options outstanding as of December 31, 2022 is zero because the fair value of the underlying Envoy Common Stock was less than the exercise price for all options as of each date.	11. The Company had a stock incentive plan (the “2003 Stock Option Plan”) that provided for the granting of stock options or other stock incentives to employees, officers, directors and consultants. The 2003 Stock Option Plan was administered by the Board, or a committee designated by the Board, which determined the persons who were to receive awards under the 2003 Stock Option Plan, the number of shares subject to each award and the term and exercise price of each award. The maximum term of options granted under the 2003 Stock Option Plan was ten years. The number of shares of common stock authorized to be issued was 6,400,000 under the 2003 Stock Option Plan. In March 2013, the Company and its stockholders adopted a new plan (the “2013 Stock Option Plan”) on substantially the same terms and conditions of the 2003 Stock Option Plan. The Company and its stockholders reserved a total of 7,000,000 On April 17, 2023, the Company and the stock option holders agreed that the stock options will be cancelled and terminated for no consideration upon the Merger. The Company uses the Black -Scholes As of December 31, 2022 and 2021, all stock options outstanding were fully vested and there was no unrecognized stock -based Options outstanding as of and for the years ended December 31, 2022 and 2021 is summarized as follows: Options Weighted- Weighted- Intrinsic Outstanding at December 31, 2021 263,000 $ 1.25 2.01 $ — Outstanding at December 31, 2022 263,000 $ 1.25 1.01 $ — Exersisable and vested at December 31, 2022 263,000 $ 1.25 1.01 $ — The aggregate intrinsic value of stock options outstanding as of December 31, 2022 and 2021 is $0 because the fair value of the underlying common stock was less than the exercise price for all options as of each date.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax [Abstract]
Income Taxes	12. The provision for income taxes consisted of the following for the years ended December 31 (in thousands): 2022 2021 Current Federal $ — $ — State — — Deferred expense (benefit) 645 1,019 Deferred tax asset valuation allowance (645 ) (1,019 ) $ — $ — The Company has incurred net operating losses since inception. A reconciliation of income tax (benefit) expense to the statutory federal tax rate is as follows: 2022 2021 Tax expense at statutory rate 21.0 % 21.0 % State income taxes, net of federal benefit 1.5 % 3.0 % Permanent items (9.5 )% (5.1 )% Federal business credits (0.6 )% (0.3 )% Valuation allowance (4.1 )% (11.6 )% Rate changes 0.8 % (2.1 )% True up of deferred balances 0.0 % 19.8 % Expiration of NOL carryovers (9.1 )% (24.2 )% Other 0.0 % (0.5 )% Effective income tax rate 0.0 % 0.0 % The tax effects of temporary differences that give rise to significant portions of the net deferred tax asset were as follows as of December 31 (in thousands): 2022 2021 Net operating loss carryforward $ 40,296 $ 40,606 Research and development credit 2,041 2,142 Other 2,081 1,025 44,418 43,773 Less: Valuation allowance (44,418 ) (43,773 ) $ — $ — The reconciliation of tax contingencies is as follows (in thousands): 2022 2021 Gross tax contingencies – January 1 $ 608 $ 577 Gross increases to tax positions in prior periods — 31 Gross decreases to tax positions in prior periods — — Lapse of statute of limitations $ (63 ) — Gross tax contingencies – December 31 $ 545 $ 608 The change in valuation allowance was $0.6 million and $1.0 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the Company had federal tax net operating loss carryforwards of approximately $177.6 million which will be available to offset earnings during the carryforward period. Additionally, as of December 31, 2022, the Company had state net operating loss carryforwards of approximately $44.0 million. If not used, these carryforwards, including federal tax carryforwards generated prior to December 31, 2017, began to expire in 2022 continuing through 2035. As a result of the Tax Cuts and Jobs Act, the federal tax net operating loss carryforwards generated in the years ended December 31, 2018 through 2022 do not expire. In addition, significant changes in ownership of the Company as defined in Section 382 of the Internal Revenue Code could put limitations on the availability of the net operating loss carryforwards. Currently, no analysis has been performed to determine the applicability of the limitations if any that may have occurred to date. As of December 31, 2022, the Company had federal research and development credits carryforwards of approximately $1.9 million. Additionally, the Company had gross state research and development credits carryforwards of approximately $0.8 million as of December 31, 2022. Both the federal and state research and development credits carryforwards will be available to offset earnings during the carryforward period. If not used, these credits will expire in 2022 through 2035. The impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the consolidated financial statements at the largest amount that is more -likely-than-not The Company has reduced its deferred tax asset for research and development credit by approximately $0.5 million and $0.6 million for uncertain tax positions as of December 31, 2022 and 2021, respectively. The Company files tax returns in the U.S. federal jurisdiction and various states. For federal income tax purposes, fiscal 2019 through 2022 tax years remain open for examination by tax authorities under the normal three -year -year

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	13. The Company leases its headquarters office space in Minnesota from a stockholder, which is considered a related party (see Note 7). The lease is considered a common control leasing arrangement. The lease liability due to the stockholder was approximately $0.6 million at September 30, 2023 and December 31, 2022. The rent expense was immaterial for the nine months ended September 30, 2023 and 2022. The Company received several loan financings from stockholders between 2012 to 2023 (see Note 9). The Company recorded a payable to related party of $4.0 million on the condensed consolidated balance sheets (see Note 5).	13. The Company leases its headquarters office space in Minnesota from a stockholder, which is considered a related party (see Note 6). The lease is considered a common control leasing arrangement. The lease liability due to the stockholder was approximately $0.7 million at December 31, 2022. The rent expense was approximately $0.1 million for the years ended December 31, 2022 and 2021. The Company received several loan financings from stockholders between 2012 to 2022 (see Note 8).

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Commitment and Contingencies [Abstract]
Commitment and Contingencies	14. The Company is party to various litigation matters arising from time to time in the ordinary course of business. In January 2020, the Company’s controlling stockholder and convertible debt holder, along with current and former directors of the Company were named in a lawsuit brought by minority stockholders (the “Spearman Plaintiffs”). This lawsuit alleges our controlling stockholder of “self -dealing -doings On August 25, 2023, the Company entered into a binding agreement in principle to settle all claims and counterclaims in the lawsuit. On September 15, 2023, the parties entered into a binding settlement agreement. The settlement agreement includes a transfer of all of the plaintiff’s stockholdings in Envoy to an entity affiliated with the majority stockholder of the Company, which was completed on September 28, 2023. The settlement agreement did not require any payment to be made by the Company. The Company has business liability insurance to cover litigation costs exceeding $50 thousand. As of September 30, 2023 and December 31, 2022, the Company has not recorded accruals for potential losses related to any existing or pending litigation claims as the Company’s management determined that there are no matters where a potential loss is probable and reasonably estimable.	14. The Company is party to various litigation matters arising from time to time in the ordinary course of business. In January 2020, the Company’s controlling stockholder and convertible debt holder, along with current and former directors of the Company were named in a lawsuit brought by minority stockholders. This lawsuit alleges our controlling stockholder of “self -dealing -doings not

Net Income (Loss) per Share

Net Income (Loss) per Share	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Net Income (Loss) per Share [Abstract]
Net Income (Loss) per Share	15. The following table sets forth the computation of basic and diluted income (loss) per share (in thousands, except share and per share amounts): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Numerator: Net income (loss) $ 1,563 $ (1,339 ) $ (25,027 ) $ (4,446 ) Less: Cumulative undeclared preferred dividends and undistributed earnings allocated to participating securities, basic (230 ) — — — Net income (loss) attributable to common stockholders, basic $ 1,360 $ (1,339 ) $ (25,027 ) $ (4,446 ) Net income (loss) $ 1,563 $ (1,339 ) $ (25,027 ) $ (4,446 ) Less: Undistributed earnings allocated to participating securities, diluted (159 ) — — — Net income (loss) attributable to common stockholders, diluted $ 1,404 $ (1,339 ) $ (25,027 ) $ (4,446 ) Denominator: Weighted average common stock outstanding, basic 10,214,183 10,123,187 10,153,564 10,123,187 Net income (loss) per share attributable to common stockholders, basic $ 0.13 $ (0.13 ) $ (2.46 ) $ (0.44 ) Weighted average common stock outstanding, diluted 11,215,068 10,123,187 10,153,564 10,123,187 Net income (loss) per share attributable to common stockholders, diluted $ 0.13 $ (0.13 ) $ (2.46 ) $ (0.44 ) The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted -average -dilutive Nine Months Ended 2023 2022 Stock options — 263,000 Series A Preferred Stock (as converted to common stock) 3,913,043 — Warrants to purchase common stock 14,166,666 — Contingent Sponsor Shares 1,000,000 — 19,079,709 263,000	15. The following table sets forth the computation of basic and diluted loss per share (in thousands, except share and per share amounts): December 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (15,923 ) $ (8,675 ) Denominator: Weighted average common stock outstanding, basic and diluted 10,123,169 10,126,825 Net loss per share attributable to common stockholders, basic and diluted $ (1.57 ) $ (0.86 ) The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti -dilutive Year Ended December 31, 2022 2021 Stock options 263,000 263,000 Warrants to purchase common stock 8,695,000 7,545,000 Convertible notes payable (related party) (as converted to common stock) 4,747,373 4,080,012 13,705,373 11,888,012

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	16. The Company has evaluated all events occurring through November 17, 2023, the date on which these unaudited condensed consolidated financial statements were issued, and during which time, nothing has occurred outside the normal course of business operations that would require disclosure, except for the following: Stock Options On October 15, 2023, the Company granted 1,938,409 stock options to certain employees and directors with an exercise price of $2.40 per share, out of which, 720,505 stock options were fully unvested on the grant date. For any employee or director that received stock options that are fully unvested on the grant date, the vesting conditions are that one -fourth -month -month Litigation On November 14, 2023, Atlas Merchant Capital SPAC Fund I LP (the “Plaintiff”), a stockholder of the Company, filed a complaint (the “Complaint”) against Daniel Hirsch, Whitney Haring -Smith -Smith The Complaint seeks specific performance to compel the Defendants to honor Atlas’ redemption request, monetary damages, attorneys’ fees and expenses. The Company believes the claims asserted in the Complaint to be without merit and intends to vigorously defend the litigation. At this time the Company does not believe that an unfavorable outcome is probable, and it is not possible to predict the outcome of the proceeding or its impact on the Company.	16. The Company has evaluated all events occurring through January 18, 2024, the date on which these consolidated financial statements were issued, and during which time, nothing has occurred outside the normal course of business operations that would require disclosure, except for as disclosed in these consolidated financial statements.

Merger

Merger	9 Months Ended
	Sep. 30, 2023
Merger [Abstract]
Merger	3. As discussed in Note 1 — Nature of the Business and Basis of Presentation, • • • • • • • • • • • • • • • • • The proceeds received by the Company from the Merger, the PIPE Transaction, and the Forward Purchase Agreement, net of transaction costs, totaled $11.7 million. The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Anzu was treated as the acquired company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Anzu, accompanied by a recapitalization. The net assets of Anzu were stated at historical cost with no goodwill or other intangible assets recorded. The following table presents the total shares of New Envoy Class A Common Stock and Series A Preferred Stock outstanding immediately after the Closing: Class A Common Stock Number of Shares Exchange of Anzu Class A Common Stock subject to possible redemption that was not redeemed for New Envoy Class A Common Stock 1,500,874 Conversion of Anzu Class B Common Stock held by the Sponsor and Anzu’s former independent director into New Envoy Class A Common Stock* 2,615,000 Subtotal – Merger, net of redemptions 4,115,874 Exchange of Envoy Common Stock for New Envoy Class A Common Stock 8,850,526 Exchange of Envoy Preferred Stock for New Envoy Class A Common Stock 1,272,055 Conversion of Convertible Notes as of September 29, 2023 into New Envoy Class A Common Stock 4,874,707 Net exercise of Envoy Warrants 2,702 Issuance of share consideration to Meteora parties 8,512 Shares recycled by Meteora parties 425,606 19,549,982 * Series A Preferred Stock Number of Shares Exchange of Anzu Class B Common Stock for Series A Preferred Stock 2,500,000 Issuance of Series A Preferred Stock in connection with the PIPE Transaction 1,000,000 Issuance of Series A Preferred Stock in connection with the conversion of the Envoy Bridge Note 1,000,000 4,500,000

Restricted Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2023
Restricted Cash [Abstract]
Restricted cash	5. Pursuant to the Envoy Bridge Note, GAT Funding, LLC contributed $1 million to subscribe for additional shares of Series A Preferred Stock at a price of $10.00 per share in order to meet the net tangible asset requirements under the Business Combination Agreement (see Note 3). Immediately prior to the Merger, GAT Funding, LLC wired $5 million to the Company to ensure the net tangible asset requirement is met. After the Merger, the subscription for additional Series A Preferred Stock was determined to be $1 million. As such, $4 million of cash is restricted and recorded as a payable to related party on the condensed consolidated balance sheets. Pursuant to the certificate of designation of the Series A Preferred Stock, the Company is required to maintain the funds allocated for the first four dividend payments in a separate account, and as such, $5.4 million of the Company’s cash has been reclassed to restricted cash (see Note 11).

Inventories

Inventories	9 Months Ended
	Sep. 30, 2023
Inventories [Abstract]
Inventories	6. Inventories, consisted of the following (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 1,227 $ 1,010 Work-in-progress 31 164 Finished goods 139 121 $ 1,397 $ 1,295

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2023
Common Stock [Abstract]
Common Stock	10. As of September 30, 2023 and December 31, 2022, the Company was authorized to issue 400,000,000 shares of New Envoy Class A Common Stock and 232,000,000 shares of Envoy Common Stock, respectively. The voting, dividend and liquidation rights of the holders of the Company’s stock are subject to and qualified by the rights, powers and preferences of the holders of the Series A Preferred Stock (see Note 11). Contingent Sponsor Shares Pursuant to the Sponsor Support Agreement, 1,000,000 shares of New Envoy Class A Common Stock held by the Sponsor shall be unvested and subject to the restrictions and forfeiture provisions set forth in the Sponsor Support Agreement (the “Contingent Sponsor Shares”). The Contingent Sponsor Shares shall vest upon the United States Food and Drug Administration’s approval of the Company’s Acclaim cochlear implant device (the “FDA Approval”). If a change of control of the Company shall occur following the Closing, then the conditions for vesting of any Contingent Sponsor Shares that remain unvested as of immediately prior to the consummation of the change of control shall be deemed to have been achieved and such Contingent Sponsor Shares shall immediately vest as of immediately prior to the consummation of such change of control. The Contingent Sponsor Shares meets the definition of a derivative, but meets the criteria to be considered indexed to the Company’s stock and the equity -classification Common Stock Warrants (Related Party) Between November 2013 and July 2022, the Company issued warrants to purchase shares of Envoy Common Stock to stockholders in connection with the issuance of the Convertible Notes and the issuance of Envoy Preferred Stock. In July 2022, the Company issued a warrant to purchase 1,150,000 shares of Envoy Common Stock to one stockholder in connection with the 2012 Convertible Note (see Note 9). Upon issuance, the holder’s exercise of the warrants was conditioned on the Company increasing its authorized shares. As there were insufficient authorized shares available at the time of issuance, the warrant was classified as a liability and measured at fair value as of December 31, 2022. The Company incurred an expense of $0.1 million upon the issuance of the warrant and $0.1 million for the change in the fair value of the warrant liability during the nine months ended September 30, 2023. On April 17, 2023, the common stock warrants were amended to provide for automatic cashless exercise or cancellation of the warrants immediately prior to the Merger. On September 29, 2023, the warrants were canceled or converted on a net exercise basis into shares of New Envoy Class A Common Stock. Out of the 8,695,000 warrants outstanding prior to the Merger, 70,000 were converted into 2,702 shares of New Envoy Class A Common Stock. Out of the remaining 8,625,000 warrants that were forfeited as part of the Business Combination, 1,150,000 were classified as a liability in the Company’s historical financial statements. The forfeiture of the liability classified warrants was recorded as a gain of $0.2 million in the unaudited condensed consolidated statements of operations and comprehensive income (loss). There were no outstanding common stock warrants (related party) as of September 30, 2023. The following table summarizes the Company’s outstanding common stock warrants (related party) as of December 30, 2022: Year of issue Numbers of Shares Exercise Expiration Date Classification 2013 70,000 $ 0.25 Nov – 2023 Equity 2015 2,300,000 $ 1.00 Nov – 2025 Equity 2017 2,300,000 $ 1.00 Aug – 2027 Equity 2018 805,000 $ 1.00 Jan – 2029 Equity 2019 920,000 $ 1.00 Dec – 2029 Equity 2021 1,150,000 $ 1.00 Dec – 2030 Equity 2022 1,150,000 $ 1.00 July – 2032 Liability 8,695,000

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Going Concern	Going ConcernSince inception, the Company has incurred cumulative losses from operations and has an accumulated deficit of $251.0 million at September 30, 2023. The Company has funded its operations and capital needs primarily through net proceeds from the issuances of convertible debt (see Note 9) and the sale of Envoy redeemable convertible preferred stock. In September 2023, the Company received $11.7 million proceeds from the Business Combination, Forward Purchase Agreement, and the PIPE Transaction, net of transaction costs. The Company had cash of $7.4 million as of September 30, 2023.Management believes that its existing cash balances combined with future capital raises, and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued. However, there can be no assurance that the Company will be successful in achieving its strategic plans, that the Company’s cash balances and future capital raises will be sufficient to support its ongoing operations, or that any additional financing will be available in a timely manner or on acceptable terms, if at all. If the Company is unable to raise sufficient financing when needed or events or circumstances occur such that the Company does not meet its strategic plans, the Company may be required to reduce certain discretionary spending, be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Company’s financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.	Going ConcernSince inception, the Company has incurred cumulative losses from operations and has an accumulated deficit of $226 million at December 31, 2022. The Company has funded its operations and capital needs primarily through net proceeds from the issuances of convertible debt (see Note 8) and the sale of preferred stock (see Note 10). The Company will need to raise additional funds to sustain its operations and to meet its long-term strategic plans and management believes it will be able to obtain additional financing to fund its operations. Management’s plans include but are not limited to seeking external sources of liquidity.Management believes that its existing cash balances combined with future capital raises, and cash receipts from products will be sufficient to fund ongoing operations through at least one year from the date the consolidated financial statements are issued. However, there can be no assurance that the Company will be successful in achieving its strategic plans, that the Company’s cash balances and future capital raises will be sufficient to support its ongoing operations, or that any additional financing will be available in a timely manner or on acceptable terms, if at all. If the Company is unable to raise sufficient financing when needed or events or circumstances occur such that the Company does not meet its strategic plans, the Company may be required to reduce certain discretionary spending, be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on the Company’s financial position, results of operations, cash flows, and ability to achieve its intended business objectives. These matters raise substantial doubt about the Company’s ability to continue as a going concern.The consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to the useful lives of property and equipment, inventory reserves, warranty liability, the fair value of common stock, the fair value of convertible notes payable, the fair value of forward purchase agreement assets, the fair value of forward purchase agreement warrant liability, the fair value of warrants and the outcome of litigation. Estimates and assumptions are reviewed periodically and the effect of changes, if any, are reflected in the unaudited condensed consolidated statements of operations and comprehensive income (loss).	Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the useful lives of property and equipment, inventory reserves, warranty liability, the fair value of common stock, the fair value of convertible notes payable, the fair value of warrants and the outcome of litigation. Estimates and assumptions are reviewed periodically and the effect of changes, if any, are reflected in the consolidated statements of operations and comprehensive loss.
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and accounts receivable, net. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. There have been no material losses on accounts receivable. There were no customers that accounted for 10.0% or more of sales for the nine months ended September 30, 2023 and September 30, 2022, respectively. There were no customers that accounted for 10.0% or more of the accounts receivable balance as of September 30, 2023 and December 31, 2022.	Concentration of Credit Risk and Significant Customers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and accounts receivable, net. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. There have been no material losses on accounts receivable. There were no customers that accounted for 10% or more of sales for the years ended December 31, 2022 and 2021, respectively. There were no customers that accounted for 10% or more of the accounts receivable balance as of December 31, 2022 and 2021.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents at December 31, 2022, and 2021. The Company maintains cash balances in bank accounts which, at times, may exceed federally insured limits.
Accounts Receivable, Net of Allowance for Doubtful Accounts		Accounts Receivable, Net of Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or other security to support amounts due. Accounts receivable are presented net of an allowance for doubtful accounts. Management performs ongoing credit evaluations of its customers based on financial information provided by the customer. Accounts receivable outstanding longer than the contractual payment terms are considered past due. The Company estimates its allowance for doubtful accounts by considering numerous factors, including delinquency trends along with ongoing customer credit evaluations. The Company writes off accounts receivable when they become uncollectible and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. The Company had no material bad debt expense and there were no material contract assets as of December 31, 2022 and 2021. The allowance for doubtful accounts was not material as of December 31, 2022 and 2021.
Inventories		Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first -in -out -downs -down -down
Property and Equipment, Net		Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in operating results. Depreciation is calculated using the straight -line
Operating Leases		Operating Leases Effective January 1, 2022, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standard Update (“ASU”) No. 2016 -02 -effect -of-use -term -lease The Company leases its headquarters office space under an operating lease with a related party. The Company also leases office space in Germany under an operating lease (see Note 6). The determination of whether an arrangement is, or contains, a lease is performed at the inception of the arrangement and as necessary at modification. Operating leases are recorded on the consolidated balance sheets with operating lease assets representing the right to use the ROU asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. The Company excludes variable lease payments in measuring ROU assets and lease liabilities, other than those that depend on an index, a rate or are in -substance ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. In addition, ROU assets include initial direct costs incurred by the lessee as well as any lease payments made at or before the commencement date and exclude lease incentives. The discount rate implicit within the Company’s leases is generally not determinable; therefore, the Company determines the discount rate using its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.
Impairment of Long-Lived Assets		Impairment of Long-Lived Assets Long -lived
Fair Value Measurement	Fair Value Measurement The Company determines the fair value of financial assets and liabilities using the fair value hierarchy established in ASC Topic 820, Fair Value Measurement • Level 1 • Level 2 • Level 3 A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company elected the fair value option for the convertible notes payable (related party) under ASC Topic 825, Financial Instruments,	Fair Value Measurement The Company determines the fair value of financial assets and liabilities using the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”). ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The hierarchy describes three levels of inputs that may be used to measure fair value, as follows: • • • A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company elected the fair value option for the convertible notes payable (related party) (“Convertible Notes”) under ASC Topic 825, Financial Instruments, with changes in fair value recorded in loss from changes in fair value of convertible notes payable (related party) each reporting period.
Redeemable Convertible Preferred Stock		Redeemable Convertible Preferred Stock The Company recorded the redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The Company classifies its redeemable convertible preferred stock outside of stockholders’ deficit on the consolidated balance sheets because, in the event of certain “liquidation events” as defined in the agreement, that are not solely within the Company’s control, the shares would become redeemable at the option of the holders. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at either of the balance sheet dates. Subsequent adjustments to increase or decrease the carrying values to the ultimate liquidation values will be made only if and when it becomes probable that such a liquidation event will occur.
Warrant Liability (Related Party)	Warrant Liability (Related Party) The Company classifies certain warrants issued to stockholders to purchase Envoy Common Stock (see Note 10) as a liability on its condensed consolidated balance sheets as these warrants are a free -standing	Warrant Liability (Related Party) The Company classifies certain warrants to purchase common stock (see Note 9) as a liability on its consolidated balance sheets (included in accrued expenses) as these warrants are a free -standing
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers -step • • • • • Revenue is recognized as performance obligations under the terms of a contract are satisfied, which generally occurs as control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using either the expected value or most likely amount method. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information that is reasonably available. The Company primarily derives revenue from the sale of its hearing device products. Revenue from product sales is recognized upon transfer of control of the product to a customer, which occurs at a point in time, at the time the Company is notified the product has been implanted or used by the customer in a surgical procedure. The Company also sells extended warranty plans on a limited basis. Revenue from extended warranty plans is recognized ratably over time and is immaterial. Amounts received from a customer prior to fulfillment of the performance obligation are included as accrued expenses on the condensed consolidated balance sheets and are immaterial as of September 30, 2023 and December 31, 2022. The Company has elected to account for shipping and handling activities performed as activities to fulfill the promise to transfer the products, and therefore these activities are not assessed as a separate performance obligation to its customers. Revenue is measured as the amount of consideration the Company expects to receive, which is based on the invoiced price. The majority of the Company’s contracts have a single performance obligation and are short term in nature. The Company’s contracts do not include variable consideration. Payment terms differ by geography and customer, but payment is generally required within 30 days from the date of product utilization. The Company also offers extended payment plans on a limited basis. Amounts due to the Company under payment plans that extend beyond 12 months are immaterial as of September 30, 2023 and December 31, 2022, therefore the Company does not adjust the promised amount of consideration for the effects of a significant financing component.	Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, which provides a five -step • • • • • Revenue is recognized as performance obligations under the terms of a contract are satisfied, which generally occurs as control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using either the expected value or most likely amount method. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information that is reasonably available. The Company primarily derives revenue from the sale of its hearing device products. Revenue from product sales is recognized upon transfer of control of the product to a customer, which occurs at a point in time, at the time the Company is notified the product has been implanted or used by the customer in a surgical procedure. The Company also sells extended warranty plans on a limited basis. Revenue from extended warranty plans is recognized ratably over time and is immaterial. Amounts received from a customer prior to fulfillment of the performance obligation are included as accrued expenses on the consolidated balance sheets and are immaterial as of December 31, 2022 and 2021. The Company has elected to account for shipping and handling activities performed as activities to fulfill the promise to transfer the products, and therefore these activities are not assessed as a separate performance obligation to its customers. Revenue is measured as the amount of consideration the Company expects to receive, which is based on the invoiced price. The majority of the Company’s contracts have a single performance obligation and are short term in nature. The Company’s contracts do not include variable consideration. Payment terms differ by geography and customer, but payment is generally required within 30 days from the date of product utilization. The Company also offers extended payment plans on a limited basis. Amounts due to the Company under payment plans that extend beyond 12 months are immaterial as of December 31, 2022 and 2021, therefore the Company does not adjust the promised amount of consideration for the effects of a significant financing component.
Cost of Goods Sold		Cost of Goods Sold Cost of goods sold is comprised of the costs of merchandise sold, as well as the related inbound freight costs and labor directly attributable to bringing certain goods to a saleable condition. In categorizing costs, the Company captures applicable depreciation and costs to maintain and run revenue generating technology, equipment related costs and any personnel -related
Product Warranty		Product Warranty The Company provides a limited warranty for implantable components. At the time product revenue is recognized, the Company reserves for estimated future costs that may be incurred under its warranties based on historical experience. The limited warranty liability is recorded in accrued expenses in the consolidated balance sheets. As of December 31, 2022 and 2021, the amount of accrued limited warranty was immaterial and the Company’s warranty payments were immaterial. During 2013, the Company offered a lifetime warranty to clinical trial patients to cover battery and surgery related costs. The Company estimates the costs that may be incurred under this lifetime warranty and records a liability in the amount of such costs at its present value. The lifetime warranty is recorded in warranty liability in the consolidated balance sheets. As of December 31, 2022 and 2021, warranty liability was $2.5 million and $3.0 million, respectively, of which $0.3 million and $0.2 million, respectively, was classified as a current liability in the consolidated balance sheets.
Patents		Patents All patent -related
Research and Development Costs		Research and Development Costs Expenditures for research and development activities are charged to operations as incurred. Research and development costs include salaries, employee benefits and laboratory testing expenses.
Stock-Based Compensation		Stock-Based Compensation The cost of employee and non -employee -Scholes -pricing
SPAC Excise Tax Liability	SPAC Excise Tax Liability The Company recognizes excise tax as an incremental cost to repurchase the treasury shares, with an offsetting tax liability recognized. The SPAC excise tax liability was recorded in accrued expenses in the Company’s condensed consolidated balance sheets.	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company has recorded a full valuation allowance against the net deferred tax asset due to the uncertainty of realizing the related benefits. The Company recognizes the financial statement benefit of a tax position only to the extent the position is more likely than not to be sustained upon audit based on the technical merits of the position. For tax positions meeting the more -likely-than-not
Foreign Currency Translation		Foreign Currency Translation The Euro is the functional currency for the Company’s foreign subsidiary in Germany and the Brazilian Real is the functional currency of the Company’s subsidiary in Brazil. The assets and liabilities of the Company’s foreign operations are translated into U.S. dollars at the end -of-the-period -average
Net Loss per Share		Net Loss per Share The Company applies the two -class -class -class Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted -average -average -converted -dilutive
Segments	Segments Operating segments are identified as components of enterprise about which discrete financial information is available for evaluation by the chief operating decision -maker	Segments Operating segments are identified as components of enterprise about which discrete financial information is available for evaluation by the chief operating decision -maker
Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Effective	Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Effective In June 2016, the FASB issued ASU No. 2016 -13 Measurement of Credit Losses on Financial Instruments -13 Other than the item noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that have a significant impact, or potential significant impact, to our unaudited condensed consolidated financial statements.	Recently Adopted Accounting Pronouncements Effective January 1, 2022, the Company adopted Topic 842. The Company utilized the effective date transition method set forth in ASU No. 2018 -11 -effect In August 2020, the FASB issued ASU No. 2020 -06 -20 -40 -06 -per-share -converted-method -06
Recently Issued Accounting Pronouncements		Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016 -13 -13 -13 -for-sale -13
Cash and Restricted Cash	Cash and Restricted Cash The Company maintains cash balances in bank accounts which, at times, may exceed federally insured limits. Restricted cash is cash the Company holds for specific reasons and is not available for immediate use.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign -currency -valued at the end of each reporting period. Derivative liabilities are classified in the condensed consolidated balance sheets as current or non -current -cash The Company accounts for its warrant liability in accordance with ASC 815 -40 -measurement The Company accounts for its Forward Purchase Agreement in accordance with ASC 815 -40 -measurement

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (restated) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Nature of the Business and Basis of Presentation [Abstarct]
Schedule of Class A Common Stock and Series A Preferred Stock Outstanding		The following table presents the total shares of New Envoy Class A Common Stock and Series A Preferred Stock outstanding immediately after the Closing: Class A Common Stock Number of Exchange of Anzu Class A Common Stock subject to possible redemption that was not redeemed for New Envoy Class A Common Stock 1,500,874 Conversion of Anzu Class B Common Stock held by the Sponsor and Anzu’s former independent director into New Envoy Class A Common Stock* 2,615,000 Subtotal – Merger, net of redemptions 4,115,874 Exchange of Envoy Common Stock for New Envoy Class A Common Stock 8,850,526 Exchange of Envoy Preferred Stock for New Envoy Class A Common Stock 1,272,055 Conversion of Convertible Notes as of September 29, 2023 into New Envoy Class A Common Stock 4,874,707 Net exercise of Envoy Warrants 2,702 Issuance of share consideration to Meteora parties 8,512 Shares recycled by Meteora parties 425,606 19,549,982 Series A Preferred Stock Number of Shares Exchange of Anzu Class B Common Stock for Series A Preferred Stock 2,500,000 Issuance of Series A Preferred Stock in connection with the PIPE Transaction 1,000,000 Issuance of Series A Preferred Stock in connection with the conversion of the Envoy Bridge 1,000,000 4,500,000
Schedule of Relevant Financial Statement	The effect of the correction of the error noted above on the relevant financial statement line items is as follows: As of September 30, 2023 As Previously Adjustments As Restated Condensed Consolidated Balance Sheet Forward purchase agreement assets 2,386 (2,386 ) — Total current assets 22,729 (2,386 ) 20,343 Total assets $ 23,601 $ (2,386 ) $ 21,215 FPA put option liability — 34 34 Forward purchase agreement warrant liability 1,793 (947 ) 846 Total current liabilities 13,603 (913 ) 12,690 Total liabilities $ 17,342 $ (913 ) $ 16,429 Additional paid-in capital 257,385 (1,473 ) 255,912 Total stockholders’ equity (deficit) $ 6,259 $ (1,473 ) $ 4,786 Total liabilities and stockholders’ equity (deficit) $ 23,601 $ (2,386 ) $ 21,215
Schedule of Condensed Consolidated Statement of Stockholders’ Equity (Deficit)	Period Ended September 30, 2023 As Previously Adjustments As Restated Condensed Consolidated Statement of Stockholders’ Equity (Deficit) Meteora forward purchase agreement shares 89 (1,473 ) (1,384 ) Additional Paid-in Capital – balance at September 30, 2023 257,385 (1,473 ) 255,912 Total stockholders’ deficit – balance at September 30, 2023 $ 6,259 $ (1,473 ) $ 4,786

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Fair Value Measurement (Tables) [Line Items]
Schedule of Company’s Liabilities Measured at Fair Value on a Recurring Basis	The following tables provide information related to the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 (in thousands): September 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Forward purchase agreement warrant liability $ — $ — $ 846 $ 846 FPA put option liability 34 34 Warrant liability 1,274 — — 1,274 $ 1,274 $ — $ 880 $ 2,154 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable, net of current portion $ — $ — $ 33,397 $ 33,397 Convertible notes payable, current portion (related party) — — 448 448 Warrant liability (related party) — — 127 127 $ — $ — $ 33,972 $ 33,972	The following tables provide information related to the Company’s liabilities measured at fair value on a recurring basis as of December 31, 2022 and December 31, 2021 (in thousands): December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable, net of current portion $ — $ — $ 33,397 $ 33,397 Convertible notes payable, current portion (related party) — — 448 448 Warrant liability (related party) — — 127 127 $ — $ — $ 33,972 $ 33,972 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities: Convertible notes payable, net of current portion $ — $ — $ 23,477 $ 23,477 $ — $ — $ 23,477 $ 23,477
Schedule of Unobservable Inputs of the Warrant Liability	The significant inputs that were used in the valuation of the Convertible Notes are presented below (in thousands, except per share amounts): December 31, 2022 Share price $ 0.33 Discount rate 14.8 % Volatility 91.0 % Probability of qualified financing 5.0 % Probability of SPAC/IPO 25.0 % Probability of default 60.0 % Probability of held to maturity 10.0 % Recovery upon default (2012 and 2013 Convertible Notes) $ 10,000	The following table presents the unobservable inputs of the warrant liability: December 31, 2022 2021 Risk-free interest rate 3.9 % Not applicable Expected dividend yield 0.0 % Not applicable Expected term (in years) 9.5 Not applicable Expected volatility 62.8 % Not applicable
Schedule of Measured at Fair Value on a Recurring Basis	The following table summarizes the activity for the Company’s Level 3 instruments measured at fair value on a recurring basis (in thousands): Convertible Warrant FPA Put Forward Balance as of December 31, 2022 $ 33,845 $ 127 $ — $ — Issuances 2,048 — — — Change in fair value 9,377 104 — — Balance as of March 31, 2023 $ 45,270 $ 231 $ — $ — Issuances 1,964 — — — Change in fair value 8,857 — — — Capital contribution (14,678 ) — — — Balance as of June 30, 2023 $ 41,413 $ 231 $ — $ — Issuances 1,964 — $ 34 $ 846 Change in fair value (4,902 ) — — — Conversion (38,475 ) (231 ) — — Balance as of September 30, 2023 $ — $ — $ 34 $ 846	The following table summarizes the activity for the Company’s Level 3 instruments measured at fair value on a recurring basis (in thousands): Convertible Warrant Balance as of December 31, 2020 $ 18,870 $ — Issuances 2,859 — Change in fair value 1,748 — Balance as of December 31, 2021 23,477 — Issuances 3,278 92 Change in fair value 7,090 35 Balance as of December 31, 2022 $ 33,845 $ 127
Schedule of Fair Value Measurements of Forward Purchase Agreement Assets	The following table presents the quantitative information regarding Level 3 fair value measurements of the forward purchase agreement assets and forward purchase agreement warrant liability: September 30, 2023 Stock price $ 5.64 Initial exercise price 10.46 Remaining term (in years) 1.00 Risk-free rate 5.32 % September 30, 2023 Underlying stock price 7.02 Exercise price 11.50 Expected term (in years) 10.00 Expected volatility 48.9 % December 31, 2022 Risk-free interest rate 3.9 % Expected dividend yield 0.0 % Expected term (in years) 9.5 Expected volatility 62.8 %
Convertible Notes Payable [Member]
Fair Value Measurement (Tables) [Line Items]
Schedule of Unobservable Inputs of the Warrant Liability		The significant inputs that were used in the valuation of the Convertible Notes include (in thousands, except per share amounts): December 31, 2022 2021 Share price $ 0.33 $ 0.29 Discount rate 14.8 % 13.9 % Volatility 91.0 % 85.0 % Probability of qualified financing 5.0 % 10.0 % Probability of SPAC/IPO 25.0 % 0 % Probability of default 60.0 % 70.0 % Probability of held to maturity 10.0 % 20.0 % Recovery upon default $ 10,000 $ 10,000

Balance Sheet Details - Curre_2

Balance Sheet Details - Current Assets and Current Liabilities (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Balance Sheet Details - Current Assets and Current Liabilities [Abstract]
​Schedule of Inventories	Inventories, consisted of the following (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 1,227 $ 1,010 Work-in-progress 31 164 Finished goods 139 121 $ 1,397 $ 1,295	Inventories, consisted of the following (in thousands): December 31, 2022 2021 Raw materials $ 1,010 $ 811 Work-in-progress 164 112 Finished goods 121 137 $ 1,295 $ 1,060
​​Schedule of Prepaid Expenses and Other Current Assets		Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2022 2021 Prepaid maintenance fees and subscriptions $ 73 $ 85 Prepaid insurance 21 21 Other prepaid expenses 35 61 $ 129 $ 167
​Schedule of Accrued Expenses		Accrued expenses consisted of the following (in thousands): December 31, 2022 2021 Inventory purchased not invoiced $ 210 $ 7 Professional fees 168 56 Payroll and benefits 96 117 Accrued warranty reserve 43 54 Accrued clinical expenses 17 16 Contract liabilities 15 15 Taxes payable 6 54 Deferred rent — 131 Other 53 25 $ 608 $ 475

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property and Equipment, Net [Abstract]
​Schedule of Property and Equipment, Net	Property and equipment, net, consisted of the following (in thousands): December 31, 2022 2021 Office equipment $ 754 $ 602 Research and development equipment 4,106 4,043 4,860 4,645 Less: Accumulated depreciation (4,529 ) (4,457 ) $ 331 $ 188

Operating Leases (Tables)

Operating Leases (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Operating Leases [Abstract]
​Schedule of The Components of Leases and Lease Costs	The components of leases and lease costs were as follows (in thousands): September 30, December 31, Operating lease right-of-use assets (related party) $ 494 $ 577 Operating lease liability, current portion (related party) $ 149 $ 125 Operating lease liabilities, net of current portion (related party) 440 565 $ 589 $ 690	The components of leases and lease costs were as follows (in thousands): December 31, 2022 Operating lease right-of-use assets (related party) $ 577 Operating lease liability, current portion (related party) $ 125 Operating lease liabilities, net of current portion (related party) 565 $ 690 December 31, 2022 Operating lease cost $ 124 $ 124
Schedule of Other Supplemental Information of Lease Amounts Recognized		Other supplemental information of lease amounts recognized in the consolidated financial statements is summarized as follows: December 31, 2022 Cash paid for amounts included in the measurement of lease liabilities $ 138 Right-of-use assets obtained in exchange for new operating lease obligations $ 696 Weighted-average remaining lease term – in years 4.9 Weighted-average discount rate 5.0 %
​​Schedule of Future Minimum Lease Payments		Future minimum lease payments associated with these leases were as follows on December 31, 2022 (in thousands): Amount 2023 $ 140 2024 161 2025 153 2026 153 2027 97 704 Less: Imputed interest (14 ) $ 690 Amount 2022 $ 141 2023 140 2024 161 2025 153 2026 153 2027 97 $ 845
Schedule of Operating Lease Cost	Nine Months Ended 2023 2022 Operating lease cost $ 97 $ 97 $ 97 $ 97
​Schedule of Other Supplemental Information	Other supplemental information of lease amounts recognized in the unaudited condensed consolidated financial statements is summarized as follows: Nine Months Ended 2023 2022 Cash paid for amounts included in the measurement of lease liabilities $ 113 $ 111
​Schedule of Weighted Average	September 30, December 31, Weighted-average remaining lease term – in years 4.2 4.9 Weighted-average discount rate 5.0 % 5.0 %
​Schedule of Future Minimum Lease Payments	Future minimum lease payments associated with these leases were as follows on September 30, 2023 (in thousands): Amount 2023 (remaining) $ 28 2024 162 2025 154 2026 155 2027 99 598 Less: Imputed interest (9 ) $ 589

Product Warranty Liability (Tab

Product Warranty Liability (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Warranty Liability [Abstract]
Schedule of Changes in Warrant Liability	Changes in warranty liability were as follows (in thousands): Amount Balance as of December 31, 2022 $ 2,478 Utilization (62 ) Balance as of March 31, 2023 $ 2,416 Reversal of product warranty accrual (45 ) Utilization (25 ) Balance as of June 30, 2023 $ 2,346 Reversal of product warranty accrual (72 ) Utilization (21 ) Balance as of September 30, 2023 $ 2,253	Changes in warranty liability were as follows (in thousands): December 31, 2022 2021 Balance at beginning of the year $ 2,998 $ 3,166 Reversal of warranty accrual (456 ) (65 ) Utilization (64 ) (103 ) Balance at end of the year $ 2,478 $ 2,998

Common Stock and Redeemable C_2

Common Stock and Redeemable Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Redeemable Convertible Preferred Stock [Abstract]
​Schedule of Redeemable Convertible Preferred Stock	The following table summarizes the Company’s outstanding common stock warrants as of December 31, 2022: Year of issue Numbers of Shares Issuable Exercise Price Expiration Date Classification 2013 70,000 $ 0.25 Nov – 2023 Equity 2015 2,300,000 $ 1.00 Nov – 2025 Equity 2017 2,300,000 $ 1.00 Aug – 2027 Equity 2018 805,000 $ 1.00 Jan – 2029 Equity 2019 920,000 $ 1.00 Dec – 2029 Equity 2021 1,150,000 $ 1.00 Dec – 2030 Equity 2022 1,150,000 $ 1.00 July – 2032 Liability 8,695,000

Stock Options (Tables)

Stock Options (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Stock Options [Abstract]
Schedule of Stock Option Activity	The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2023: Options Weighted- Weighted- Intrinsic Value Outstanding at December 31, 2022 263,000 $ 1.25 1.01 $ — Outstanding at September 30, 2022 — n/a n/a n/a Exercisable and vested at September 30, 2023 — n/a n/a n/a	Options outstanding as of and for the years ended December 31, 2022 and 2021 is summarized as follows: Options Weighted- Weighted- Intrinsic Outstanding at December 31, 2021 263,000 $ 1.25 2.01 $ — Outstanding at December 31, 2022 263,000 $ 1.25 1.01 $ — Exersisable and vested at December 31, 2022 263,000 $ 1.25 1.01 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax [Abstract]
​Schedule of Provision for Income Taxes	The provision for income taxes consisted of the following for the years ended December 31 (in thousands): 2022 2021 Current Federal $ — $ — State — — Deferred expense (benefit) 645 1,019 Deferred tax asset valuation allowance (645 ) (1,019 ) $ — $ —
​​Schedule of Reconciliation of Income Tax (Benefit) Expense	A reconciliation of income tax (benefit) expense to the statutory federal tax rate is as follows: 2022 2021 Tax expense at statutory rate 21.0 % 21.0 % State income taxes, net of federal benefit 1.5 % 3.0 % Permanent items (9.5 )% (5.1 )% Federal business credits (0.6 )% (0.3 )% Valuation allowance (4.1 )% (11.6 )% Rate changes 0.8 % (2.1 )% True up of deferred balances 0.0 % 19.8 % Expiration of NOL carryovers (9.1 )% (24.2 )% Other 0.0 % (0.5 )% Effective income tax rate 0.0 % 0.0 %
​​​Schedule of Net Deferred Tax Asset	The tax effects of temporary differences that give rise to significant portions of the net deferred tax asset were as follows as of December 31 (in thousands): 2022 2021 Net operating loss carryforward $ 40,296 $ 40,606 Research and development credit 2,041 2,142 Other 2,081 1,025 44,418 43,773 Less: Valuation allowance (44,418 ) (43,773 ) $ — $ —
Schedule of​ Reconciliation of Tax Contingencies	The reconciliation of tax contingencies is as follows (in thousands): 2022 2021 Gross tax contingencies – January 1 $ 608 $ 577 Gross increases to tax positions in prior periods — 31 Gross decreases to tax positions in prior periods — — Lapse of statute of limitations $ (63 ) — Gross tax contingencies – December 31 $ 545 $ 608

Net Income (Loss) per Share (Ta

Net Income (Loss) per Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Net Income (Loss) per Share [Abstract]
​Schedule of Basic and Diluted Loss Per Share	The following table sets forth the computation of basic and diluted income (loss) per share (in thousands, except share and per share amounts): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Numerator: Net income (loss) $ 1,563 $ (1,339 ) $ (25,027 ) $ (4,446 ) Less: Cumulative undeclared preferred dividends and undistributed earnings allocated to participating securities, basic (230 ) — — — Net income (loss) attributable to common stockholders, basic $ 1,360 $ (1,339 ) $ (25,027 ) $ (4,446 ) Net income (loss) $ 1,563 $ (1,339 ) $ (25,027 ) $ (4,446 ) Less: Undistributed earnings allocated to participating securities, diluted (159 ) — — — Net income (loss) attributable to common stockholders, diluted $ 1,404 $ (1,339 ) $ (25,027 ) $ (4,446 ) Denominator: Weighted average common stock outstanding, basic 10,214,183 10,123,187 10,153,564 10,123,187 Net income (loss) per share attributable to common stockholders, basic $ 0.13 $ (0.13 ) $ (2.46 ) $ (0.44 ) Weighted average common stock outstanding, diluted 11,215,068 10,123,187 10,153,564 10,123,187 Net income (loss) per share attributable to common stockholders, diluted $ 0.13 $ (0.13 ) $ (2.46 ) $ (0.44 )	The following table sets forth the computation of basic and diluted loss per share (in thousands, except share and per share amounts): December 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (15,923 ) $ (8,675 ) Denominator: Weighted average common stock outstanding, basic and diluted 10,123,169 10,126,825 Net loss per share attributable to common stockholders, basic and diluted $ (1.57 ) $ (0.86 )
Schedule of Potentially Dilutive Securities Have Been Excluded From the Computation of Diluted Net	The Company excluded the following potential shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to stockholders for the periods indicated because including them would have had an anti -dilutive Nine Months Ended 2023 2022 Stock options — 263,000 Series A Preferred Stock (as converted to common stock) 3,913,043 — Warrants to purchase common stock 14,166,666 — Contingent Sponsor Shares 1,000,000 — 19,079,709 263,000	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti -dilutive Year Ended December 31, 2022 2021 Stock options 263,000 263,000 Warrants to purchase common stock 8,695,000 7,545,000 Convertible notes payable (related party) (as converted to common stock) 4,747,373 4,080,012 13,705,373 11,888,012

Merger (Tables)

Merger (Tables)	9 Months Ended
	Sep. 30, 2023
Merger [Abstract]
Schedule of Class A Common Stock and Series A Preferred Stock Outstanding	The following table presents the total shares of New Envoy Class A Common Stock and Series A Preferred Stock outstanding immediately after the Closing: Class A Common Stock Number of Shares Exchange of Anzu Class A Common Stock subject to possible redemption that was not redeemed for New Envoy Class A Common Stock 1,500,874 Conversion of Anzu Class B Common Stock held by the Sponsor and Anzu’s former independent director into New Envoy Class A Common Stock* 2,615,000 Subtotal – Merger, net of redemptions 4,115,874 Exchange of Envoy Common Stock for New Envoy Class A Common Stock 8,850,526 Exchange of Envoy Preferred Stock for New Envoy Class A Common Stock 1,272,055 Conversion of Convertible Notes as of September 29, 2023 into New Envoy Class A Common Stock 4,874,707 Net exercise of Envoy Warrants 2,702 Issuance of share consideration to Meteora parties 8,512 Shares recycled by Meteora parties 425,606 19,549,982 * Series A Preferred Stock Number of Shares Exchange of Anzu Class B Common Stock for Series A Preferred Stock 2,500,000 Issuance of Series A Preferred Stock in connection with the PIPE Transaction 1,000,000 Issuance of Series A Preferred Stock in connection with the conversion of the Envoy Bridge Note 1,000,000 4,500,000

Inventories (Tables)

Inventories (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Inventories [Abstract]
Schedule of Inventories	Inventories, consisted of the following (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 1,227 $ 1,010 Work-in-progress 31 164 Finished goods 139 121 $ 1,397 $ 1,295	Inventories, consisted of the following (in thousands): December 31, 2022 2021 Raw materials $ 1,010 $ 811 Work-in-progress 164 112 Finished goods 121 137 $ 1,295 $ 1,060

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2023
Common Stock [Abstract]
Schedule of Outstanding Common Stock Warrants	The following table summarizes the Company’s outstanding common stock warrants (related party) as of December 30, 2022: Year of issue Numbers of Shares Exercise Expiration Date Classification 2013 70,000 $ 0.25 Nov – 2023 Equity 2015 2,300,000 $ 1.00 Nov – 2025 Equity 2017 2,300,000 $ 1.00 Aug – 2027 Equity 2018 805,000 $ 1.00 Jan – 2029 Equity 2019 920,000 $ 1.00 Dec – 2029 Equity 2021 1,150,000 $ 1.00 Dec – 2030 Equity 2022 1,150,000 $ 1.00 July – 2032 Liability 8,695,000

Nature of the Business and Ba_3

Nature of the Business and Basis of Presentation (restated) (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended
	Apr. 17, 2023	Sep. 30, 2023	Jun. 30, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022		Sep. 29, 2023	Sep. 30, 2022	Dec. 31, 2021		Dec. 31, 2017
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Purchased shares						425,606
Prepayment amount (in Dollars)					$ 4,500,000	$ 4,500,000
Shares issued					8,512	8,512
Preferred stock par value (in Dollars per share)		$ 0.01			$ 0.01	$ 0.01
Aggregate purchase price (in Dollars)	$ 10,000,000					$ 10,000,000
Common stock Shares outstanding						139,153,144
Exercise of converted shares						2,702
Converted shares	2,702
Converted shares					2,615,000	2,615,000
Shares issued		8,695,000			8,695,000	8,695,000
Sponsor forfeited shares					5,510,000	5,510,000
Warrant shares		14,166,666			14,166,666	8,695,000				7,545,000
Sponsor exchanged shares					2,500,000	2,500,000
Shares of forfeiture					2,500,000	2,500,000
Share consideration					8,512	8,512
Warrant exercisable shares										263,000
Purchase transaction price (in Dollars per share)					$ 10	$ 10
Purchase cost (in Dollars)					$ 10,000,000	$ 10
Preferred stock shares issued						4,500,000
Contributed additional (in Dollars)					$ 1,000,000	$ 1,000,000
Additional shares					100,000	100,000
Unvested shares		1,000,000			1,000,000
Purchased shares					425,606
Initial fair value (in Dollars)					$ 51,400,000
Additional fair value (in Dollars)		$ 36,800,000			36,800,000
Difference of fair value net (in Dollars)		14,600,000			14,600,000
Convertible notes payable related party (in Dollars)		$ 4,000,000			4,000,000
Fair value of convertible notes payable related party (in Dollars)			$ 91,000	$ 91,000
Other expenses (in Dollars)					$ 300,000
Minimum [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Convertible notes payable related party (in Dollars)			14,600,000	14,600,000
Maximum [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Convertible notes payable related party (in Dollars)			$ 14,700,000	$ 14,700,000
Convertible Notes [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Conversion price per share (in Dollars per share)		$ 1			$ 1
Private Placement Warrants [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Warrant shares		14,166,666			14,166,666	14,166,666
Forward Purchase Agreement Asset [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Prepayments (in Dollars)		$ 2,400,000			$ 2,400,000
Class A Common Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Common stock par value (in Dollars per share)						$ 0.0001
Common stock Shares outstanding						8,850,526
Convertible shares						4,874,707
Converted shares					20,000,000	20,000,000
Shares issued		1,272,055			1,272,055	1,272,055
Common stock par value (in Dollars per share)		$ 0.0001			$ 0.0001	$ 0.0001	[1]	$ 0.0001		$ 0.0001	[1]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 11.5			$ 11.5	$ 11.5
Forward purchase shares					490,000	490,000
Warrant exercisable shares		3,874,394			3,874,394	3,874,394
Unvested shares						1,000,000
Series A Preferred Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Shares issued	1,000,000					1,000,000
Aggregate number of shares	1,000,000					1,000,000
Preferred stock par value (in Dollars per share)		$ 0.0001			$ 0.0001	$ 0.0001	[1]			$ 0.0001	[1]
Price per share (in Dollars per share)	$ 10	$ 10.98			$ 10.98	$ 10
Forward purchase shares					1,000,000	1,000,000
Preferred stock shares issued		4,500,000			4,500,000	0	[1]			0	[1]	2,000,000
Series A Preferred Stock [Member] | Preferred Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Preferred stock par value (in Dollars per share)	$ 0.0001					$ 0.0001
Sponsor exchanged shares		2,500,000
Purchased shares		1,000,000
Envoy Preferred Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Converted shares					4,000,000	4,000,000
Common Class B [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Common stock par value (in Dollars per share)		$ 0.0001			$ 0.0001	$ 0.0001
Sponsor [Member] | Private Placement Warrants [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Warrant shares		12,500,000			12,500,000	12,500,000
Series A Preferred Stock [Member] | GAT Funding LLC [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Preferred stock shares issued						1,000,000
Convertible Notes [Member] | Class A Common Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Common stock par value (in Dollars per share)		$ 0.01			$ 0.01
Series of Individually Immaterial Business Acquisitions [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Common stock shares					14,999,990	14,999,990
Business combination per share (in Dollars per share)		$ 10			$ 10	$ 10
Net of transaction costs (in Dollars)		$ 11,700,000			$ 11,700,000	$ 11,700,000
Series of Individually Immaterial Business Acquisitions [Member] | Class A Common Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) [Line Items]
Common stock shares					0.063603	0.063603
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Nature of the Business and Ba_4

Nature of the Business and Basis of Presentation (restated) (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding - shares		12 Months Ended
		Sep. 29, 2023	Sep. 30, 2023	Dec. 31, 2022	[2]	Dec. 31, 2021	[2]
Nature of the Business and Basis of Presentation (restated) (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding [Line Items]
Total common stock outstanding		19,549,982
Total preferred stock outstanding		4,500,000
Class A Common Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding [Line Items]
Exchange of Anzu Class A Common Stock subject to possible redemption that was not redeemed for New Envoy Class A Common Stock		1,500,874
Conversion of Anzu Class B Common Stock held by the Sponsor and Anzu’s former independent director into New Envoy Class A Common Stock*	[1]	2,615,000
Subtotal – Merger, net of redemptions		4,115,874
Exchange of Envoy Common Stock for New Envoy Class A Common Stock		8,850,526
Exchange of Envoy Preferred Stock for New Envoy Class A Common Stock		1,272,055
Conversion of Convertible Notes as of September 29, 2023 into New Envoy Class A Common Stock		4,874,707
Net exercise of Envoy Warrants		2,702
Issuance of share consideration to Meteora parties		8,512
Shares recycled by Meteora parties		425,606
Total common stock outstanding			19,549,982	10,122,581		10,123,187
Series B Preferred Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding [Line Items]
Exchange of Anzu Class B Common Stock for Series A Preferred Stock		2,500,000
Series A Preferred Stock [Member]
Nature of the Business and Basis of Presentation (restated) (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding [Line Items]
Exchange of Anzu Class B Common Stock for Series A Preferred Stock		2,500,000
Issuance of Series A Preferred Stock in connection with the PIPE Transaction		1,000,000
Issuance of Series A Preferred Stock in connection with the conversion of the Envoy Bridge Note		1,000,000
Total preferred stock outstanding			4,500,000	0		0
[1]1,000,000 shares of the New Envoy Class A Common Stock are unvested and subject to restrictions and forfeitures per the Sponsor Support Agreement. These shares will vest upon the FDA approval of Acclaim or upon a change of control of the Company (see Note 10)[2]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Accumulated deficit	$ (251,012)		$ (225,985)	$ (210,062)
Warranty liability			2,500	3,000
Warranty liability			300	$ 200
Operating lease asset			577		$ 700
Operating lease liabilities	589		$ 845		$ 800
Accumulated deficit	251,000
Purchase agreement	11,700
Cash	$ 7,400
Customer accounted percentage	10%	10%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Customer accounted percentage			10%
Accounts Receivable [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Customer accounted percentage	10%		10%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Customer accounted percentage				10%

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Apr. 17, 2023
Fair Value Measurement (Details) [Line Items]
Convertible notes decrease		$ 2,600,000
Discount rate increase or decrease		62.80%
Expected dividend yield	0%
Measurement Input, Default Rate [Member]
Fair Value Measurement (Details) [Line Items]
Percentage of probability default	5%	5%
Discount rate increase or decrease		60%	70%
Measurement Input, Discount Rate [Member]
Fair Value Measurement (Details) [Line Items]
Percentage of probability default	5%
Discount rate increase or decrease		14.80%	13.90%
Minimum [Member]
Fair Value Measurement (Details) [Line Items]
Convertible notes decrease		$ 1,500,000
Convertible Notes		1.5
Maximum [Member]
Fair Value Measurement (Details) [Line Items]
Convertible notes decrease		1,600,000
Convertible Notes		$ 1,600,000
Series A Preferred Stock [Member]
Fair Value Measurement (Details) [Line Items]
Price per share	$ 10.98	$ 10		$ 10
Convertible Notes Payable [Member] | Measurement Input, Discount Rate [Member]
Fair Value Measurement (Details) [Line Items]
Discount rate increase or decrease		5%
Convertible Note [Member]
Fair Value Measurement (Details) [Line Items]
Convertible Notes	$ 2,600,000

Fair Value Measurement (Detai_2

Fair Value Measurement (Details) - Schedule of Company’s Liabilities Measured at Fair Value on a Recurring Basis - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Liabilities:
Liabilities, fair value	$ 2,154	$ 33,972
Convertible Notes Payable Net of Current Portion Related Party [Member]
Liabilities:
Liabilities, fair value		33,397	$ 23,477
Convertible Notes Payable Current Portion Related Party [Member]
Liabilities:
Liabilities, fair value		448
Warrant liability [Member]
Liabilities:
Liabilities, fair value		127	23,477
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Liabilities, fair value	1,274
Fair Value, Inputs, Level 1 [Member] | Convertible Notes Payable Net of Current Portion Related Party [Member]
Liabilities:
Liabilities, fair value
Fair Value, Inputs, Level 1 [Member] | Convertible Notes Payable Current Portion Related Party [Member]
Liabilities:
Liabilities, fair value
Fair Value, Inputs, Level 1 [Member] | Warrant liability [Member]
Liabilities:
Liabilities, fair value
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Liabilities, fair value
Fair Value, Inputs, Level 2 [Member] | Convertible Notes Payable Net of Current Portion Related Party [Member]
Liabilities:
Liabilities, fair value
Fair Value, Inputs, Level 2 [Member] | Convertible Notes Payable Current Portion Related Party [Member]
Liabilities:
Liabilities, fair value
Fair Value, Inputs, Level 2 [Member] | Warrant liability [Member]
Liabilities:
Liabilities, fair value
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Liabilities, fair value	$ 880	33,972
Fair Value, Inputs, Level 3 [Member] | Convertible Notes Payable Net of Current Portion Related Party [Member]
Liabilities:
Liabilities, fair value		33,397	23,477
Fair Value, Inputs, Level 3 [Member] | Convertible Notes Payable Current Portion Related Party [Member]
Liabilities:
Liabilities, fair value		448
Fair Value, Inputs, Level 3 [Member] | Warrant liability [Member]
Liabilities:
Liabilities, fair value		$ 127	$ 23,477

Fair Value Measurement (Detai_3

Fair Value Measurement (Details) - Schedule of Valuation of the Convertible Notes - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	62.80%
Recovery upon default (in Dollars)	$ 10,000	$ 10,000
Share price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share price (in Dollars per share)	$ 0.33	$ 0.29
Discount rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	14.80%	13.90%
Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	91%	85%
Probability of qualified financing [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	5%	10%
Probability of SPAC/IPO [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	25%	0%
Probability of default [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	60%	70%
Probability of held to maturity [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	10%	20%

Fair Value Measurement (Detai_4

Fair Value Measurement (Details) - ​Schedule of Unobservable Inputs of the Warrant Liability	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Unobservable Inputs Of The Warrant Liability Abstract
Risk-free interest rate	3.90%
Expected dividend yield	0%
Expected term (in years)	9 years 6 months
Expected volatility	62.80%

Fair Value Measurement (Detai_5

Fair Value Measurement (Details) - ​Schedule of Measured at Fair Value on a Recurring Basis - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Convertible Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance Beginning	$ 23,477	$ 18,870
Issuances	3,278	2,859
Change in fair value	7,090	1,748
Balance Ending	33,845	23,477
Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance Beginning
Issuances	92
Change in fair value	35
Balance Ending	$ 127

Balance Sheet Details - Curre_3

Balance Sheet Details - Current Assets and Current Liabilities (Details) - ​Schedule of Inventories - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
​Schedule of Inventories [Abstract]
Raw materials	$ 1,227	$ 1,010	$ 811
Work-in-progress	31	164	112
Finished goods	139	121	137
Total Inventories	$ 1,397	$ 1,295	$ 1,060

Balance Sheet Details - Curre_4

Balance Sheet Details - Current Assets and Current Liabilities (Details) - ​​Schedule of Prepaid Expenses and Other Current Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2023
​​Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepaid maintenance fees and subscriptions	$ 73	$ 85
Prepaid insurance	21	21
Other prepaid expenses	35	61
Prepaid expenses and other current assets	$ 129	$ 167	$ 997

Balance Sheet Details - Curre_5

Balance Sheet Details - Current Assets and Current Liabilities (Details) - ​Schedule of Accrued Expenses - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
​Schedule of Accrued Expenses [Abstract]
Inventory purchased not invoiced		$ 210	$ 7
Professional fees		168	56
Payroll and benefits		96	117
Accrued warranty reserve		43	54
Accrued clinical expenses		17	16
Contract liabilities		15	15
Taxes payable		6	54
Deferred rent			131
Other		53	25
Total Accrued expenses	$ 4,052	$ 608	$ 475

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property and Equipment, Net [Abstract]
Depreciation expense	$ 85	$ 49	$ 75	$ 71

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - ​Schedule of Property and Equipment, Net - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Office equipment		$ 4,860	$ 4,645
Less: Accumulated depreciation		(4,529)	(4,457)
Property and equipment, net	$ 378	331	188
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Office equipment		754	602
Research and development equipment [Member]
Property, Plant and Equipment [Line Items]
Office equipment		$ 4,106	$ 4,043

Operating Leases (Details)

Operating Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Operating Leases [Line Items]
Operating leases rent expenses	$ 124

Operating Leases (Details) - _S

Operating Leases (Details) - ​Schedule of the Components of Leases and Lease Costs - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jan. 01, 2022
Operating Leases (Details) - ​Schedule of the Components of Leases and Lease Costs [Line Items]
Operating lease right-of-use assets (related party)			$ 577	$ 700
Operating lease liability, current portion (related party)			125
Operating lease liabilities, net of current portion (related party)			565
Operating lease total	$ 589		690
Operating lease cost	97	$ 97	124
Operating lease cost total	$ 97	$ 97	124
Previously Reported [Member]
Operating Leases (Details) - ​Schedule of the Components of Leases and Lease Costs [Line Items]
Operating lease total			$ 690

Operating Leases (Details) - Sc

Operating Leases (Details) - Schedule of Other Supplemental Information of Lease Amounts Recognized - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2023
​​Schedule of Weighted Average {Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 138
Right-of-use assets obtained in exchange for new operating lease obligations	$ 696
Weighted-average remaining lease term – in years	4 years 10 months 24 days	4 years 2 months 12 days
Weighted-average discount rate	5%	5%

Operating Leases (Details) - __

Operating Leases (Details) - ​​Schedule of Future Minimum Lease Payments - USD ($) $ in Thousands	Dec. 31, 2027	Dec. 31, 2026	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Jan. 01, 2022
Operating Leases (Details) - ​​Schedule of Future Minimum Lease Payments [Line Items]
2023					$ 140	$ 162	$ 141
2024				$ 161	$ 140	154
2025			$ 153	$ 161		155
2026		$ 153	$ 153			99
2027	$ 97	$ 153
2027	$ 97
Total lease Payment						598	704
Less: Imputed interest						(9)	(14)
Total						$ 589	845	$ 800
Previously Reported [Member]
Operating Leases (Details) - ​​Schedule of Future Minimum Lease Payments [Line Items]
Total							$ 690

Product Warranty Liability (Det

Product Warranty Liability (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Warranty Liability [Abstract]
Estimated cost (in Dollars)	$ 6		$ 6
Average battery life	5 years	5 years
Percentage of average patient life	3.60%	3.60%	2.40%
Discount rate		5%	2.80%
Discount rate	5%

Product Warranty Liability (D_2

Product Warranty Liability (Details) - ​Schedule of Changes in Warrant Liability - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Changes in Warrant Liability [Abstract]
Balance at beginning			$ 2,478	$ 2,998	$ 3,166
Reversal of warranty accrual	$ (72)	$ (45)		(456)	(65)
Utilization	$ (21)	$ (25)	$ (62)	(64)	(103)
Balance at end				$ 2,478	$ 2,998

Convertible Notes Payable (Re_2

Convertible Notes Payable (Related Party) (Details) - USD ($)		1 Months Ended			3 Months Ended		9 Months Ended	12 Months Ended
	Apr. 17, 2023	Jun. 30, 2022	Nov. 30, 2021	Mar. 31, 2021	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Convertible Notes Payable (Related Party) (Details) [Line Items]
Cost of Issuance								$ 10,000,000	$ 10,000,000
Percentage of price per share					80%		80%
Convertible note					$ 4,000,000		$ 4,000,000
Drawn amount		$ 10,000,000		$ 10,000,000			2,000,000
Convertible note								$ 59,000,000
Borrowing capacity	$ 10,000,000				$ 4,000,000		$ 4,000,000
Percentage of interest rate	4.50%
Maturity date	Dec. 31, 2025
Preferred Stock, conversion price (in Dollars per share)					$ 11.5		$ 11.5	$ 11.5
Common Stock, conversion price (in Dollars per share)							$ 1
Net tangible assets					$ 5,000,000		$ 5,000,000
Class A Common Stock [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Preferred Stock, conversion price (in Dollars per share)								0.01	$ 20,000,000
Series A Preferred Stock [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Common stock per share (in Dollars per share)								4,000,000	$ 1,272,055
Preferred Stock, conversion price (in Dollars per share)					$ 10		$ 10	$ 10
Envoy Bridge Note [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Drawn amount							$ 5,000,000
2012 Convertible Note [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Percentage of interest per annum							4.50%
Price per share (in Dollars per share)					$ 1		$ 1
Percentage of price per share					80%		80%
2012 Convertible Note [Member] | Class A Common Stock [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Price per share (in Dollars per share)					$ 15.72		$ 15.72
Convertible Note [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Undrawn principal amount								$ 5,000,000
New stock					$ 2,500,000		$ 2,500,000
Principal amount	$ 4,000,000					$ 4,000,000		59,700,000
Common stock per share (in Dollars per share)					$ 1		$ 1
2013 Convertible Notes [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Percentage of interest per annum							4.50%
Price per share (in Dollars per share)					$ 1		$ 1
Percentage of price per share					80%		80%
Principal amount								700,000
2013 Convertible Notes [Member] | Class A Common Stock [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Price per share (in Dollars per share)					$ 15.72		$ 15.72
2013 Convertible Notes [Member] | Series A Preferred Stock [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Price per share (in Dollars per share)					$ 10		$ 10
Envoy Bridge Note [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Drawn amount					$ 3,000,000	$ 3,000,000
Convertible Notes Payable (Related Party) [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Outstanding principal amount								$ 59,700,000	$ 51,700,000
Percentage of interest per annum								4.50%
Convertible Notes Payable (Related Party) [Member] | 2012 Convertible Note [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Outstanding principal amount								$ 59,000,000	51,000,000
Percentage of interest per annum								4.50%
Additional withdrawn amount		$ 10,000,000		$ 10,000,000
Issuance received								$ 8,000,000	8,000,000
Cost of Issuance								3,300,000	2,900,000
Undrawn principal amount								$ 5,000,000	3,000,000
Price per share (in Dollars per share)								$ 1
Percentage of price per share								80%
Convertible Notes Payable (Related Party) [Member] | 2013 Convertible Note [Member]
Convertible Notes Payable (Related Party) (Details) [Line Items]
Outstanding principal amount								$ 700,000	$ 700,000
Percentage of interest per annum								4.50%
Price per share (in Dollars per share)								$ 1
Percentage of price per share								80%
New stock								$ 2,500,000
Effective conversion price (in Dollars per share)								$ 1
Convertible note			$ 50,000
Accrued interest			$ 18,000

Common Stock and Redeemable C_3

Common Stock and Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended		12 Months Ended
	Apr. 17, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2017	Dec. 31, 2015	Jul. 31, 2022
Redeemable Convertible Preferred Stock [Line Items]
Share authorised				400,000,000		232,000,000
Preferred stock authorized				100,000,000
Preferred stock par value (in Dollars per share)		$ 0.01		$ 0.01
Shares issued				4,500,000
Preferred stock price per share (in Dollars per share)				$ 15
Aggregate proceeds (in Dollars)			$ 92	$ 92		$ 58		$ 10,000	$ 10,000
Purchase warrants	70,000							2,300,000	2,300,000
Preferred stock conversion price (in Dollars per share)		$ 11.5		$ 11.5
Shares issued				425,606
Number of warrants issued		14,166,666		8,695,000		7,545,000
Incurred expense for issuance of warrant (in Dollars)				$ 100
Purchase warrants	8,695,000									1,150,000
Conversion of shares issued	2,702
Warrants forfeited	8,625,000
Business combination shares classified as liability	1,150,000
Gain on warrant liability (in Dollars)	$ 200
Sponsor [Member]
Redeemable Convertible Preferred Stock [Line Items]
Shares issued		1,000,000		1,000,000
Redeemable Preferred Stock [Member]
Redeemable Convertible Preferred Stock [Line Items]
Preferred stock authorized		10,000,000		10,000,000		10,000,000
Shares issued									2,000,000
Preferred Stock [Member] | Series A Preferred Stock [Member]
Redeemable Convertible Preferred Stock [Line Items]
Preferred stock par value (in Dollars per share)						$ 0.01
Series A Preferred Stock [Member]
Redeemable Convertible Preferred Stock [Line Items]
Preferred stock authorized		10,000,000		0
Preferred stock par value (in Dollars per share)		$ 0.0001		$ 0.0001	[1]	$ 0.0001	[1]
Shares issued		4,500,000		0	[1]	0	[1]	2,000,000
Preferred stock price per share (in Dollars per share)		$ 10		$ 10				$ 5	$ 5
Preferred stock conversion price (in Dollars per share)		$ 10		10
Price per share (in Dollars per share)				$ 4,000,000		$ 1,272,055
Common Class A [Member]
Redeemable Convertible Preferred Stock [Line Items]
Share authorised		400,000,000		232,000,000
Preferred stock price per share (in Dollars per share)		$ 15
Preferred stock conversion price (in Dollars per share)				$ 0.01		$ 20,000,000
Two Thousand Twelve Convertible Note [Member]
Redeemable Convertible Preferred Stock [Line Items]
Number of warrants issued										1,150,000
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Common Stock and Redeemable C_4

Common Stock and Redeemable Convertible Preferred Stock (Details) - ​Schedule of Redeemable Convertible Preferred Stock - $ / shares								9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2013	Sep. 30, 2023
Preferred Units [Line Items]
Numbers of Shares Issuable	8,695,000							8,695,000
Two Thousand Thirteen [Member]
Preferred Units [Line Items]
Numbers of Shares Issuable							70,000	70,000
Exercise Price							$ 0.25	$ 0.25
Classification							Nov – 2023	Nov – 2023
Expiration Date							Equity	Equity
Two Thousand Fifteen [Member]
Preferred Units [Line Items]
Numbers of Shares Issuable						2,300,000		2,300,000
Exercise Price						$ 1		$ 1
Classification						Nov – 2025		Nov – 2025
Expiration Date						Equity		Equity
Two Thousand Seventeen [Member]
Preferred Units [Line Items]
Numbers of Shares Issuable					2,300,000			2,300,000
Exercise Price					$ 1			$ 1
Classification					Aug – 2027			Aug – 2027
Expiration Date					Equity			Equity
Two Thousand Eighteen [Member]
Preferred Units [Line Items]
Numbers of Shares Issuable				805,000				805,000
Exercise Price				$ 1				$ 1
Classification				Jan – 2029				Jan – 2029
Expiration Date				Equity				Equity
Two Thousand Nineteen [Member]
Preferred Units [Line Items]
Numbers of Shares Issuable			920,000					920,000
Exercise Price			$ 1					$ 1
Classification			Dec – 2029					Dec – 2029
Expiration Date			Equity					Equity
Two Thousand Twenty One [Member]
Preferred Units [Line Items]
Numbers of Shares Issuable		1,150,000						1,150,000
Exercise Price		$ 1						$ 1
Classification		Dec – 2030						Dec – 2030
Expiration Date		Equity						Equity
Two Thousand Twenty Two [Member]
Preferred Units [Line Items]
Numbers of Shares Issuable	1,150,000							1,150,000
Exercise Price	$ 1							$ 1
Classification	July – 2032							July – 2032
Expiration Date	Liability							Liability

Series A Preferred Stock (Detai

Series A Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2017	Dec. 31, 2015
Series A Preferred Stock (Details) [Line Items]
Preferred stock authorized (in Shares)		100,000,000
Preferred stock par value	$ 0.01	$ 0.01
Shares issued (in Shares)		4,500,000
Additional capital (in Dollars)	$ 1	$ 1
Preferred stock price per share		$ 15
Preferred stock conversion price	$ 11.5	11.5
Preferred stock outstanding	15	15
Original issuance price	$ 10	$ 10
Percentage of additional dividend	12%	12%
Net tangible assets (in Dollars)	$ 10	$ 10
Unpaid cash dividends		$ 10
Dividend payments (in Dollars)	$ 5.4
Series A Preferred Stock [Member]
Series A Preferred Stock (Details) [Line Items]
Preferred stock authorized (in Shares)	10,000,000	0
Preferred stock par value	$ 0.0001	$ 0.0001	[1]	$ 0.0001	[1]
Shares issued (in Shares)	4,500,000	0	[1]	0	[1]	2,000,000
Additional capital (in Dollars)	$ 1
Preferred stock price per share	$ 10	$ 10				$ 5	$ 5
Preferred stock conversion price	$ 10	$ 10
Original issuance price	12%	12%
Unpaid cash dividends	$ 10
Redeemable Preferred Stock [Member]
Series A Preferred Stock (Details) [Line Items]
Preferred stock authorized (in Shares)	10,000,000	10,000,000		10,000,000
Shares issued (in Shares)							2,000,000
Class A Common Stock [Member]
Series A Preferred Stock (Details) [Line Items]
Preferred stock price per share	$ 15
Preferred stock conversion price		$ 0.01		$ 20,000,000
Preferred stock outstanding	$ 10	$ 10
Restated [Member]
Series A Preferred Stock (Details) [Line Items]
Preferred stock authorized (in Shares)	100,000,000
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Stock Options (Details)

Stock Options (Details) - 2003 Stock Option Plan [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Stock Options (Details) [Line Items]
Shareholders reserved	7,000,000
Intrinsic value (in Dollars)		$ 0	$ 0
Common Stock [Member]
Stock Options (Details) [Line Items]
Common stock, authorized	6,400,000
Maximum [Member]
Stock Options (Details) [Line Items]
Common stock available issuance	6,400,000
Minimum [Member]
Stock Options (Details) [Line Items]
Common stock available issuance	552,000
2003 Stock Option Plan [Member]
Stock Options (Details) [Line Items]
Common stock, authorized		6,400,000
2003 Stock Option Plan [Member] | Maximum [Member]
Stock Options (Details) [Line Items]
Common stock available issuance		6,400,000
2003 Stock Option Plan [Member] | Minimum [Member]
Stock Options (Details) [Line Items]
Common stock available issuance		552,000
2013 Stock Option Plan [Member]
Stock Options (Details) [Line Items]
Shareholders reserved		7,000,000

Stock Options (Details) - Sched

Stock Options (Details) - Schedule of Stock Option Activity - USD ($)			12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Schedule of Stock Option Activity [Abstract]
Options, Opening Balance	263,000		263,000
Weighted-average Exercise Price per Option, Opening Balance	$ 1.25		$ 1.25
Weighted-average Remaining Contractual Term, Opening Balance	1 year 3 days		2 years 3 days
Intrinsic Value, Opening Balance
Options, Ending Balance	263,000		263,000	263,000
Weighted-average Exercise Price per Option, Ending Balance				$ 1.25
Weighted-average Remaining Contractual Term, Ending Balance				1 year 3 days
Intrinsic Value, Ending Balance
Options, Exersisable and vested				263,000
Weighted-average Exercise Price per Option, Exersisable and vested				$ 1.25
Weighted-average Remaining Contractual Term, Exersisable and vested				1 year 3 days
Intrinsic Value, Exersisable and vested

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax [Abstract]
Change in valuation allowance	$ 0.6	$ 1
Net operating loss carryforwards	177.6
State net operating loss carryforwards	44
Research and development credits carryforwards	1.9
Additional research and development credits carryforwards	0.8
Deferred tax asset reduced for R&D cost	$ 0.5	$ 0.6

Income Taxes (Details) - _Sched

Income Taxes (Details) - ​Schedule of Provision for Income Taxes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current
Federal
State
Deferred expense (benefit)	645	1,019
Deferred tax asset valuation allowance	(645)	(1,019)
Provision for income taxes

Income Taxes (Details) - __Sche

Income Taxes (Details) - ​​Schedule of Reconciliation of Income Tax (Benefit) Expense	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
​​Schedule of Reconciliation of Income Tax (Benefit) Expense [Abstract]
Tax expense at statutory rate	21%	21%
State income taxes, net of federal benefit	1.50%	3%
Permanent items	(9.50%)	(5.10%)
Federal business credits	(0.60%)	(0.30%)
Valuation allowance	(4.10%)	(11.60%)
Rate changes	0.80%	(2.10%)
True up of deferred balances	0%	19.80%
Expiration of NOL carryovers	(9.10%)	(24.20%)
Other	0%	(0.50%)
Effective income tax rate	0%	0%

Income Taxes (Details) - ___Sch

Income Taxes (Details) - ​​​Schedule of Net Deferred Tax Asset - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
​​​Schedule of Net Deferred Tax Asset [Abstract]
Net operating loss carryforward	$ 40,296	$ 40,606
Research and development credit	2,041	2,142
Other	2,081	1,025
Deferred tax asset gross	44,418	43,773
Less: Valuation allowance	(44,418)	(43,773)
Deferred tax asset net

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of​ Reconciliation of Tax Contingencies - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Reconciliation of Tax Contingencies [Abstract]
Gross tax contingencies – January 1	$ 608	$ 577
Gross increases to tax positions in prior periods		31
Gross decreases to tax positions in prior periods
Lapse of statute of limitations	(63)
Gross tax contingencies – December 31	$ 545	$ 608

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2023
Related Party Transactions (Details) [Line Items]
Lease liability due	$ 0.6		$ 0.6
Rent expense	0.1	$ 0.1
Notes payable			$ 4
Previously Reported [Member]
Related Party Transactions (Details) [Line Items]
Lease liability due	$ 0.7

Commitment and Contingencies (D

Commitment and Contingencies (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Commitment and Contingencies [Abstract]
Litigation costs	$ 50,000	$ 50,000
Accruals for potential losses			$ 0

Net Income (Loss) per Share (De

Net Income (Loss) per Share (Details) - ​Schedule of Basic and Diluted Loss Per Share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022		Dec. 31, 2021
Numerator:
Net loss attributable to common shareholders	$ 1,360	$ (1,339)	$ (25,027)	$ (4,446)	$ (15,923)		$ (8,675)
Denominator:
Weighted average common stock outstanding, basic	10,214,183	10,123,187	10,153,564	10,123,187	10,123,169	[1]	10,126,825	[1]
Net loss per share attributable to common shareholders, basic	$ 0.13	$ (0.13)	$ (2.46)	$ (0.44)	$ (1.57)		$ (0.86)
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Net Income (Loss) per Share (_2

Net Income (Loss) per Share (Details) - ​Schedule of Basic and Diluted Loss Per Share (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Schedule of Basic and Diluted Loss Per Share [Abstract]
Weighted average common stock outstanding, diluted (in Shares)	11,215,068	10,123,187	10,153,564	10,123,187	10,123,169	10,126,825
Net loss per share attributable to common shareholders, diluted (in Dollars per share)	$ 0.13	$ (0.13)	$ (2.46)	$ (0.44)	$ (1.57)	$ (0.86)

Net Income (Loss) per Share (_3

Net Income (Loss) per Share (Details) - Schedule of Potentially Dilutive Securities Have Been Excluded From the Computation of Diluted Net - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 30, 2022
Schedule of Potentially Dilutive Securities Have Been Excluded From the Computation of Diluted Net [Abstract]
Stock options			263,000	263,000	263,000
Warrants to purchase common stock	14,166,666		8,695,000	7,545,000
Convertible notes payable (related party) (as converted to common stock)	3,913,043		4,747,373	4,080,012
Total	19,079,709	263,000	13,705,373	11,888,012

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Oct. 15, 2023 $ / shares shares
Subsequent Events [Line Items]
Granted shares (in Shares)	1,938,409
Exercise price (in Dollars per share) | $ / shares	$ 2.4
Stock option share (in Shares)	720,505
Received stock options rate	25%
Stock option rate	75%
Minimum [Member]
Subsequent Events [Line Items]
Received stock options rate	25%
Median [Member]
Subsequent Events [Line Items]
Received stock options rate	50%
Maximum [Member]
Subsequent Events [Line Items]
Received stock options rate	75%

Nature of the Business and Ba_5

Nature of the Business and Basis of Presentation (Restated) (Details) - Schedule of Relevant Financial Statement - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
As Previously Reported [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Forward purchase agreement assets	$ 2,386
Total current assets	22,729
Total assets	23,601
FPA put option liability
Forward purchase agreement warrant liability	1,793
Total current liabilities	13,603
Total liabilities	17,342
Additional paid-in capital	257,385
Total stockholders’ equity (deficit)	6,259	$ (36,195)	$ (24,987)
Total liabilities and stockholders’ equity (deficit)	23,601
Adjustments [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Forward purchase agreement assets	(2,386)
Total current assets	(2,386)
Total assets	(2,386)
FPA put option liability	34
Forward purchase agreement warrant liability	(947)
Total current liabilities	(913)
Total liabilities	(913)
Additional paid-in capital	(1,473)
Total stockholders’ equity (deficit)	(1,473)
Total liabilities and stockholders’ equity (deficit)	(2,386)
As Restated [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Forward purchase agreement assets
Total current assets	20,343
Total assets	21,215
FPA put option liability	34
Forward purchase agreement warrant liability	846
Total current liabilities	12,690
Total liabilities	16,429
Additional paid-in capital	255,912
Total stockholders’ equity (deficit)	4,786
Total liabilities and stockholders’ equity (deficit)	$ 21,215

Nature of the Business and Ba_6

Nature of the Business and Basis of Presentation (Restated) (Details) - Schedule of Condensed Consolidated Statement of Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
As Previously Reported [Member]
Nature of the Business and Basis of Presentation (Restated) (Details) - Schedule of Condensed Consolidated Statement of Stockholders’ Equity (Deficit) [Line Items]
Meteora forward purchase agreement shares	$ 89
Additional paid-in capital	257,385
Total stockholders’ equity (deficit)	6,259	$ (36,195)	$ (24,987)
Adjustments [Member]
Nature of the Business and Basis of Presentation (Restated) (Details) - Schedule of Condensed Consolidated Statement of Stockholders’ Equity (Deficit) [Line Items]
Meteora forward purchase agreement shares	(1,473)
Additional paid-in capital	(1,473)
Total stockholders’ equity (deficit)	(1,473)
As Restated [Member]
Nature of the Business and Basis of Presentation (Restated) (Details) - Schedule of Condensed Consolidated Statement of Stockholders’ Equity (Deficit) [Line Items]
Meteora forward purchase agreement shares	(1,384)
Additional paid-in capital	255,912
Total stockholders’ equity (deficit)	$ 4,786

Merger (Details)

Merger (Details) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Apr. 17, 2023	Sep. 30, 2023	Dec. 31, 2022		Sep. 29, 2023	Sep. 30, 2022	Dec. 31, 2021		Dec. 31, 2017
Merger (Details) [Line Items]
Share Outstanding			139,153,144
Converted shares		2,615,000	2,615,000
Preferred stock, par value (in Dollars per share)		$ 0.01	$ 0.01
Conversion of Stock, Shares Issued	2,702
Shares of new envoy		8,695,000	8,695,000
Sponsor forfeited shares		5,510,000	5,510,000
Warrant shares		14,166,666	8,695,000				7,545,000
Sponsor exchanged shares		2,500,000	2,500,000
Shares of forfeiture		2,500,000	2,500,000
Share consideration		8,512	8,512
Warrant exercisable shares							263,000
Purchase transaction price (in Dollars per share)		$ 10	$ 10
Purchase cost (in Dollars)		$ 10,000,000	$ 10
Preferred stock shares issued			4,500,000
Contributed additional (in Dollars)		$ 1,000,000	$ 1,000,000
Additional shares		100,000	100,000
Unvested shares		1,000,000
Class A Common Stock [Member]
Merger (Details) [Line Items]
Share Outstanding			8,850,526
Converted shares		20,000,000	20,000,000
Shares of new envoy		1,272,055	1,272,055
Common stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001	[1]	$ 0.0001		$ 0.0001	[1]
Warrant exercisable price (in Dollars per share)		$ 11.5	$ 11.5
Forward purchase shares		490,000	490,000
Warrant exercisable shares		3,874,394	3,874,394
Unvested shares			1,000,000
New Envoy Class A Common Stock [Member]
Merger (Details) [Line Items]
Share Outstanding		139,153,144
Converted shares		8,850,526
Converted shares		4,874,707
Envoy Preferred Stock [Member]
Merger (Details) [Line Items]
Conversion of Stock, Shares Issued		4,000,000	4,000,000
Class B Common Stock [Member]
Merger (Details) [Line Items]
Common stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001
Series A Preferred Stock [Member]
Merger (Details) [Line Items]
Preferred stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001	[1]			$ 0.0001	[1]
Forward purchase shares		1,000,000	1,000,000
Preferred stock shares issued		4,500,000	0	[1]			0	[1]	2,000,000
Class A Common Stock [Member]
Merger (Details) [Line Items]
Warrant shares		14,166,666	14,166,666
Sponsor [Member] | Class A Common Stock [Member]
Merger (Details) [Line Items]
Warrant shares		12,500,000	12,500,000
GAT Funding LLC [Member] | Series A Preferred Stock [Member]
Merger (Details) [Line Items]
Preferred stock shares issued		1,000,000
Warrant [Member] | New Envoy Class A Common Stock [Member]
Merger (Details) [Line Items]
Converted shares		2,702
Business Combination Agreement [Member]
Merger (Details) [Line Items]
Business combination shares		14,999,990	14,999,990
Business combination per share (in Dollars per share)		$ 10	$ 10
Net of transaction costs (in Dollars)		$ 11,700,000	$ 11,700,000
Business Combination Agreement [Member] | Class A Common Stock [Member]
Merger (Details) [Line Items]
Business combination shares		0.063603	0.063603
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Merger (Details) - Schedule of

Merger (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding - shares		12 Months Ended
		Sep. 29, 2023	Sep. 30, 2023	Dec. 31, 2022	[2]	Dec. 31, 2021	[2]
Merger (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding [Line Items]
Total common stock outstanding		19,549,982
Total preferred stock outstanding		4,500,000
Class A Common Stock [Member]
Merger (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding [Line Items]
Exchange of Anzu Class A Common Stock subject to possible redemption that was not redeemed for New Envoy Class A Common Stock		1,500,874
Conversion of Anzu Class B Common Stock held by the Sponsor and Anzu’s former independent director into New Envoy Class A Common Stock	[1]	2,615,000
Subtotal - Merger, net of redemptions		4,115,874
Exchange of Envoy Common Stock for New Envoy Class A Common Stock		8,850,526
Exchange of Envoy Preferred Stock for New Envoy Class A Common Stock		1,272,055
Conversion of Convertible Notes as of September 29, 2023 into New Envoy Class A Common Stock		4,874,707
Net exercise of Envoy Warrants		2,702
Issuance of share consideration to Meteora parties		8,512
Shares recycled by Meteora parties		425,606
Total common stock outstanding			19,549,982	10,122,581		10,123,187
Series A Preferred Stock [Member]
Merger (Details) - Schedule of Class A Common Stock and Series A Preferred Stock Outstanding [Line Items]
Exchange of Anzu Class B Common Stock for Series A Preferred Stock		2,500,000
Issuance of Series A Preferred Stock in connection with the PIPE Financing		1,000,000
Issuance of Series A Preferred Stock in connection with the conversion of the Envoy Bridge Note		1,000,000
Total preferred stock outstanding			4,500,000	0		0
[1]1,000,000 shares of the New Envoy Class A Common Stock are unvested and subject to restrictions and forfeitures per the Sponsor Support Agreement. These shares will vest upon the FDA approval of Acclaim or upon a change of control of the Company (see Note 10)[2]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Fair Value Measurement (Restate

Fair Value Measurement (Restated) (Details) - Schedule of Company’s Liabilities Measured at Fair Value on a Recurring Basis - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Liabilities:
Forward purchase agreement warrant liability	$ 846
FPA put option liability	34
Warrant liability	1,274
Total warrant liability	2,154	$ 33,972
Liabilities:
Convertible notes payable, net of current portion (related party)		33,397
Convertible notes payable, current portion (related party)		448
Warrant liability (related party)		127
Total liability		33,972
Level 1 [Member]
Liabilities:
Forward purchase agreement warrant liability
FPA put option liability
Warrant liability	1,274
Total warrant liability	1,274
Liabilities:
Convertible notes payable, net of current portion (related party)
Convertible notes payable, current portion (related party)
Warrant liability (related party)
Total liability
Level 2 [Member]
Liabilities:
Forward purchase agreement warrant liability
FPA put option liability
Warrant liability
Total warrant liability
Liabilities:
Convertible notes payable, net of current portion (related party)
Convertible notes payable, current portion (related party)
Warrant liability (related party)
Total liability
Level 3 [Member]
Liabilities:
Forward purchase agreement warrant liability	846
FPA put option liability	34
Warrant liability
Total warrant liability	$ 880	33,972
Liabilities:
Convertible notes payable, net of current portion (related party)		33,397
Convertible notes payable, current portion (related party)		448
Warrant liability (related party)		127
Total liability		$ 33,972

Fair Value Measurement (Resta_2

Fair Value Measurement (Restated) (Details) - Schedule of Fair Value Measurements of Forward Purchase Agreement Assets - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value Measurement (Restated) (Details) - Schedule of Fair Value Measurements of Forward Purchase Agreement Assets [Line Items]
Expected term (in years)		9 years 6 months
Expected volatility		62.80%
Risk-free rate		3.90%
Expected dividend yield	0%
Forward Purchase Agreement [Member]
Fair Value Measurement (Restated) (Details) - Schedule of Fair Value Measurements of Forward Purchase Agreement Assets [Line Items]
Stock price (in Dollars per share)	$ 5.64
Exercise price (in Dollars per share)	$ 10.46
Expected term (in years)	1 year
Risk-free rate	5.32%
Warrant Liability [Member]
Fair Value Measurement (Restated) (Details) - Schedule of Fair Value Measurements of Forward Purchase Agreement Assets [Line Items]
Expected term (in years)		9 years 6 months
Expected volatility		62.80%
Risk-free rate		3.90%
Expected dividend yield		0%
Level 3 [Member]
Fair Value Measurement (Restated) (Details) - Schedule of Fair Value Measurements of Forward Purchase Agreement Assets [Line Items]
Stock price (in Dollars per share)	$ 7.02
Exercise price (in Dollars per share)	$ 11.5
Expected term (in years)	10 years
Expected volatility	48.90%

Fair Value Measurement (Resta_3

Fair Value Measurement (Restated) (Details) - Schedule of Valuation of the Convertible Notes - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share price (in Dollars per share)	$ 0.33
Discount rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	14.80%	13.90%
Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	91%	85%
Probability of qualified financing [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	5%	10%
Probability of SPAC/IPO [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	25%	0%
Probability of default [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	60%	70%
Probability of held to maturity [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation of the convertible notes, rate	10%	20%
2023 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Recovery upon default (Convertible Notes) (in Dollars)	$ 10,000

Fair Value Measurement (Resta_4

Fair Value Measurement (Restated) (Details) - Schedule of Measured at Fair Value on a Recurring Basis - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Convertible Notes and Envoy Bridge Note (Related Party) [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance Beginning	$ 41,413	$ 45,270	$ 33,845
Issuances	1,964	1,964	2,048
Capital contribution		(14,678)
Conversion	(38,475)
Change in fair value	(4,902)	8,857	9,377
Balance Ending		41,413	45,270
Warrant Liability (Related Party) [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance Beginning	231	231	127
Issuances
Capital contribution
Conversion	(231)
Change in fair value			104
Balance Ending		231	231
FPA Put Option Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance Beginning
Issuances	34
Capital contribution
Conversion
Change in fair value
Balance Ending	34
Forward Purchase Agreement Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance Beginning
Issuances	846
Capital contribution
Conversion
Change in fair value
Balance Ending	$ 846

Restricted Cash (Details)

Restricted Cash (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Restricted Cash (Details) [Line Items]
Additional shares	$ 1	$ 1
Net tangible asset	5
Reclassed to restricted cash	5.4
Series A Preferred Stock [Member]
Restricted Cash (Details) [Line Items]
Additional shares	$ 1
Net tangible (in Dollars per share)	$ 10
Envoy Bridge Note, GAT Funding, LLC [Member]
Restricted Cash (Details) [Line Items]
Restricted cash	$ 4

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Inventories [Abstract]
Raw materials	$ 1,227	$ 1,010	$ 811
Work-in-progress	31	164	112
Finished goods	139	121	137
Total	$ 1,397	$ 1,295	$ 1,060

Operating Leases (Details) - _2

Operating Leases (Details) - ​Schedule of Lease Costs - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Operating Leases (Details) - ​Schedule of Lease Costs [Line Items]
Operating lease right-of-use assets (related party)		$ 577	$ 700
Operating lease liability, current portion (related party)		125
Operating lease liabilities, net of current portion (related party)	$ 589	845	$ 800
Total	589	690
Related Party [Member]
Operating Leases (Details) - ​Schedule of Lease Costs [Line Items]
Operating lease right-of-use assets (related party)	494	577
Operating lease liability, current portion (related party)	149	125
Operating lease liabilities, net of current portion (related party)	$ 440	$ 565

Operating Leases (Details) - _3

Operating Leases (Details) - Schedule of Operating Lease Cost - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Schedule of Operating Lease Cost [Abstract]
Operating lease cost	$ 97	$ 97	$ 124
Total	$ 97	$ 97	$ 124

Operating Leases (Details) - _4

Operating Leases (Details) - ​Schedule of Other Supplemental Information - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
​Schedule of Other Supplemental Information [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 113	$ 111

Operating Leases (Details) - _5

Operating Leases (Details) - ​Schedule of Weighted Average	Sep. 30, 2023	Dec. 31, 2022
​Schedule of Weighted Average [Abstract]
Weighted-average remaining lease term - in years	4 years 2 months 12 days	4 years 10 months 24 days
Weighted-average discount rate	5%	5%

Operating Leases (Details) - _6

Operating Leases (Details) - ​Schedule of Future Minimum Lease Payments - USD ($) $ in Thousands	Dec. 31, 2026	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Jan. 01, 2022
​Schedule of Future Minimum Lease Payments [Abstract]
2023 (remaining)					$ 28
2024				$ 140	162	$ 141
2025			$ 161	$ 140	154
2026		$ 153	$ 161		155
2027	$ 153	$ 153			99
Total					598	704
Less: Imputed interest					(9)	(14)
Total					$ 589	$ 845	$ 800

Product Warranty Liability (D_3

Product Warranty Liability (Details) - Schedule of Changes in Warrant Liability - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Changes in Warrant Liability [Abstract]
Balance Beginning	$ 2,346	$ 2,416	$ 2,478
Utilization	(21)	(25)	(62)	$ (64)	$ (103)
Balance Ending	2,253	2,346	$ 2,416	2,478
Reversal of product warranty accrual	$ (72)	$ (45)		$ (456)	$ (65)

Common Stock (Details)

Common Stock (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended		12 Months Ended
	Apr. 17, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2017	Dec. 31, 2015	Jul. 31, 2022
Common Stock (Details) [Line Items]
Share authorized				400,000,000	232,000,000
Shares issued				425,606
Purchase warrants	8,695,000							1,150,000
Incurred expenses (in Dollars)		$ 100
Change in fair value of warrant liability (in Dollars)			$ 92	$ 92	$ 58	$ 10,000	$ 10,000
Shares converted	70,000					2,300,000	2,300,000
Conversion of shares issued	2,702
Warrants forfeited	8,625,000
Business combination shares classified as liability	1,150,000
Gain on warrant liability (in Dollars)	$ 200
Sponsor [Member]
Common Stock (Details) [Line Items]
Shares issued		1,000,000		1,000,000
Class A Common Stock [Member]
Common Stock (Details) [Line Items]
Share authorized		400,000,000		232,000,000
Common Stock Warrants (Related Party) [Member]
Common Stock (Details) [Line Items]
Change in fair value of warrant liability (in Dollars)		$ 100

Common Stock (Details) - Schedu

Common Stock (Details) - Schedule of Outstanding Common Stock Warrants - $ / shares								9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2013	Sep. 30, 2023
Class of Warrant or Right [Line Items]
Numbers of Shares Issuable	8,695,000							8,695,000
2013 [Member]
Class of Warrant or Right [Line Items]
Numbers of Shares Issuable							70,000	70,000
Exercise Price							$ 0.25	$ 0.25
Classification							Equity	Equity
Expiration Date							Nov – 2023	Nov – 2023
2015 [Member]
Class of Warrant or Right [Line Items]
Numbers of Shares Issuable						2,300,000		2,300,000
Exercise Price						$ 1		$ 1
Classification						Equity		Equity
Expiration Date						Nov – 2025		Nov – 2025
2017 [Member]
Class of Warrant or Right [Line Items]
Numbers of Shares Issuable					2,300,000			2,300,000
Exercise Price					$ 1			$ 1
Classification					Equity			Equity
Expiration Date					Aug – 2027			Aug – 2027
2018 [Member]
Class of Warrant or Right [Line Items]
Numbers of Shares Issuable				805,000				805,000
Exercise Price				$ 1				$ 1
Classification				Equity				Equity
Expiration Date				Jan – 2029				Jan – 2029
2019 [Member]
Class of Warrant or Right [Line Items]
Numbers of Shares Issuable			920,000					920,000
Exercise Price			$ 1					$ 1
Classification			Equity					Equity
Expiration Date			Dec – 2029					Dec – 2029
2021 [Member]
Class of Warrant or Right [Line Items]
Numbers of Shares Issuable		1,150,000						1,150,000
Exercise Price		$ 1						$ 1
Classification		Equity						Equity
Expiration Date		Dec – 2030						Dec – 2030
2022 [Member]
Class of Warrant or Right [Line Items]
Numbers of Shares Issuable	1,150,000							1,150,000
Exercise Price	$ 1							$ 1
Classification	Liability							Liability
Expiration Date	July – 2032							July – 2032

Stock Options (Details) - Sch_2

Stock Options (Details) - Schedule of Stock Option Activity - USD ($)			12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Schedule of Stock Option Activity [Abstract]
Options, Opening Balance	263,000		263,000
Weighted-average Exercise Price per Option, Opening Balance	$ 1.25		$ 1.25
Weighted-average Remaining Contractual Term, Opening Balance	1 year 3 days		2 years 3 days
Intrinsic Value, Opening Balance
Options, Ending Balance	263,000		263,000	263,000
Weighted-average Exercise Price per Option, Ending Balance				$ 1.25
Weighted-average Remaining Contractual Term, Ending Balance				1 year 3 days
Intrinsic Value, Ending Balance
Options, Exersisable and vested				263,000
Weighted-average Exercise Price per Option, Exersisable and vested				$ 1.25
Weighted-average Remaining Contractual Term, Exersisable and vested				1 year 3 days
Intrinsic Value, Exersisable and vested

Net Income (Loss) per Share (_4

Net Income (Loss) per Share (Details) - ​Schedule of Basic and Diluted Loss Per Share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022		Dec. 31, 2021
Numerator:
Net income (loss)	$ 1,563	$ (1,339)	$ (25,027)	$ (4,446)
Less: Cumulative undeclared preferred dividends and undistributed earnings allocated to participating securities, basic	(230)
Net income (loss) attributable to common stockholders, basic	1,360	(1,339)	(25,027)	(4,446)	$ (15,923)		$ (8,675)
Less: Undistributed earnings allocated to participating securities, diluted	(159)
Net income (loss) attributable to common stockholders, diluted	$ 1,404	$ (1,339)	$ (25,027)	$ (4,446)
Denominator:
Weighted average common stock outstanding, basic (in Shares)	10,214,183	10,123,187	10,153,564	10,123,187	10,123,169	[1]	10,126,825	[1]
Net income (loss) per share attributable to common stockholders, basic (in Dollars per share)	$ 0.13	$ (0.13)	$ (2.46)	$ (0.44)	$ (1.57)		$ (0.86)
Weighted average common stock outstanding, diluted (in Shares)	11,215,068	10,123,187	10,153,564	10,123,187	10,123,169		10,126,825
Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share)	$ 0.13	$ (0.13)	$ (2.46)	$ (0.44)	$ (1.57)		$ (0.86)
[1]The number of shares of redeemable convertible preferred stock, Series A Preferred Stock and Class A Common stock issued and outstanding prior to the Merger have been retroactively adjusted by the Exchange Ratio to give effect to the reverse recapitalization treatment of the Merger. See Note 1 — Nature of the Business and Basis of Presentation for more information.

Net Income (Loss) per Share (_5

Net Income (Loss) per Share (Details) - Schedule of Potentially Dilutive Securities Have Been Excluded from the Computation of Diluted Net - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Schedule of Potentially Dilutive Securities Have Been Excluded From the Computation of Diluted Net [Abstract]
Stock options		263,000
Series A Preferred Stock (as converted to common stock)	3,913,043		4,747,373	4,080,012
Warrants to purchase common stock	14,166,666		8,695,000	7,545,000
Contingent Sponsor Shares	1,000,000
Total	19,079,709	263,000	13,705,373	11,888,012